INDEX

Volume Thirty-three — January through December 1999

The Annals of Pharmacotherapy

JANUARY	Pages 1-136	MAY	Pages 519-664	OCTOBER	Pages 1023-1135
FEBRUARY	Pages 137-274	JUNE	Pages 665-762	NOVEMBER	Pages 1136-1242
MARCH	Pages 275-396	JULY/AUGUST	Pages 763-892	DECEMBER	Pages 1243-1399
APRIL	Pages 397-518	SEPTEMBER	Pages 893-1022		

SUBJECT INDEX

A-B

ABBOTTBASE, calculation error (L), 1230

Abciximab, management of acute coronary syndromes (A), 715 Acenocoumarol, acetaminophen interactions (L.), 506; mic oral gel interactions (CR), 175

Acetaminophen, acenoc ol interactions (L), 506; overdose, coma, and acidosis (CR), 1191

Acetylcholinesterase inhibitors, Alzheimer disease therapy (A), 182, 441; switch a. : digent community clinic (L.), 872

Achilles tendonitis, levofloxacin induction (CR), 792 Acidosis, acetaminophen overdose (CR), 1191; aminoc

high anion gap metabolic acidosis association (CR), 308 ACIP, recommended childhood immunization schedule (NC), 270 Acquired immunodeficiency syndrome, see Human in ficiency virus

Acral erythema, high-dose methotrexate infusion (L), 646 Adenosine Aza receptor, schizophrenia role (A), 480

Adherence, see Compliance Adverse drug reactions, acetaminophen (CR), 1191; alopecia from psychotropic medications (A), 631; aminocaproic acid, high anion gap metabolic acidosis (CR), 308; amlodipine (L), 126; amoxicillin/clavulanate (VO), 109; (CR), 560; amphotericin B (CR), 683; anagrelide (A), 1118; atypical antipsychotics (A), 210; azithromycin, intravenous, review (A), 224; bromfenac (CR), 945; bromocriptine (CR), 1050; bupropion (CR), 305, 931; candesart cilexetil, review (A), 1295; carbamazepine (CR), 571; cisapride syncopy (L.), 251; clozapine (A), 623; (L.), 1008; codofovir iritis (RR), 167; dexrazoxane-CHOP therapy (L.), 253; domperidone (A), 435; doxepin in neonates (CR), 690; elderly receiving home health services (RR), 1147; emergency department, medication-re lated visits (RR), 1252; epoprostenol (A), 345; erythromycin, Stevens-Johnson syndrome (VO), 1369; fenofibrate (A), 1086; fluconazole-carbamazepine (CR), 790; fluvoxamine-metoclo-pramide (L), 382; haloperidol (CR), 1046; headache (A), 61; hy-drochlorothiazide-induced pulmonary edema (CR), 172; ibuprofen (CR), 693; ibutilide, review (A), 43; indinavir-associated rash (RR), 17; interferon alpha-2a, photosensitive seizures (L.), 113; intravenous immune globulin (CR), 800; lamivudine (A), 1109; lamotrigine (RR), 1037; levofloxacin (CR), 792; losartan (CR), 933; (CR), 936; methotrexate (L), 646; metoclopramide (CR), 35; (L), 644; milnacipran (L), 1009; montelukast (A), 1307; naltrexone rhabdomyolysis (CR), 312; naratriptan (A), 708; nelfinavir mesylate (A), 331; nifuroxazide (L), 1229; nightmares (A), 93; olanzapine seizure (CR), 554; (CR), 787; oxacillin (CR), 1060; oxaprozin (CR), 942; paclitaxel (CR), 584; pentamidine (L), 5 phenytoin (L), 111; (VO), 748; prevention, Iran (IR), 236; pro cainamide (CR), 948; protamine (CR), 927; quinine-induced totoxicity (CR), 32; reteplase (A), 320; rifampin, pill-induced esophagitis (CR), 27; rifapentine (A), 1206; raloxifene (A) 1324; risperidone, mania (L), 380; sertralin–venlafaxine (L), 381; sibutramine (A), 974; sulfadiazine (L), 379; tolterodine (A), 1078; trovafloxacin (A), 55, (VO), 1122; valproate (A), 1211, (L), 1370; vancomycin (CR), 1043; venlafaxine (L), 1009; vigabatrin, re e, ototoxicity (CR), 423; vitamin E (A), 1199 Albumin, dilution of 25% human preparation and hemolysis (NC).

Albuterol, delivery systems for infants (RR), 141; hyperkaler ent (A), 103; nebulized versus metered-dose inhalers for infants (RR), 144

Alendronate, climical trials (A), 593; compared with etidronate (A), 596; costs (A), 596; pharmacokinetics (A), 589; pharmacology (A), 588; osteoporosis treatment (A), 587; safety (A), 596 All-traxes-retimoic acid, sublingual admi leukemia patient (L), 503

Allen, Loyd V Jr. president, American Pharmaceutical As Academy of Pharmaceutical Research and Science (NC), 135 Allergy, Corticosteroid allergic-type reactions (A), 451; latex allergy, risk from medication vial closures (A), 373

Allopurinol, desensitization (CR), 1180 Alopecia, psychotropic medications as cause (A), 631

Alteplase, therapy in extracorporeal membrane oxygo

Alternative medicine, see Nonprescription medi

Alzheimer disease, acetylcholinesterase inhibitor therapy (A), 441; antioxidants, antihypertensives, and ergoloid derivative estrogen for dementia-related aggression in men (CR), 808; genetic research (A), 179; hormonal and emerging investigational drug therapies (A), 178; nonsteroidal antiinflammatory drug therapies (A), 178; nonsteroidal antiinflammatory drug therapies (A), 178; nonsteroidal antiinflammatory drug therapies (B), 179; nonsteroidal antiinflammatory (B), 179; nonsteroidal antiinflammatory (B), 179; nonstero apy (A), 840; pharmacologic interventions (L), 1374

Ambulatory care, adverse events in elderly receiving home health services (RR), 1147; cimetidine effects on phenytoin concentra-tions in seizure patients (RR), 769; follow-up phone calls to com munity pharmacies in Medicaid drug utilization program (RR), 541; glucose, home blood monitoring (A), 355; impact of phareutical services (A), 1336; over-the-counter drug pres patterns (RR), 400; prothrombin time, handheld monitoring devices (RR), 775

Amikacin, dosing for pediatric bronchopneumonia (L.), 749 Amiodipine, compared with candesartan cilexetil (A), 1294 Aminocaproic acid, high anion gap metabolic acidosis associations

es, once-daily treatment for gram-positive endo carditis (A), 600; utilization and monitoring in Hong Kong oncol-

ogy patients (L), 646 Amiodarone, scrum levels, effects of antiretroviral therapy (L), 645 Amitriptyline, headache, management of medication-induced (A),

ne, doxing when converting from nifedin

lease (RR), 7; thrombocytopenia induction (L), 1126 Amoxicillin/clavullinic acid, crythema multiforme following expr sure (VO), 109; hepatic failure with progression to Stevens-Johnson syndrome (CR), 560

Ampakines, Alzheimer disease treatment (A), 184 Amphetamines, counteract opioid-induced sedation (CR), 1362; niehtmares (A), 93

Amphotericin B, hepatotoxicity (CR), 683

Anagrelide, adverse effects (A), 1118; clinical trials (A), 1117; dosing (A), 1117; pharmacology (A), 1117; thrombocytosis treatment (A), 1116

Anaphylaxis, methylxanthine use (A), 1001; vancomycin induction (CR), 1043

ngioedema, losartan induction (CR), 933; (CR), 936 Angiotensin-converting enzyme, polymorphism and type I diabet-ic nephropathy (A), 474

Angiotensin-converting enzyme inhibitors, Alzheimer disease treatment (A), 193; aspirin interactions (A), 375; creatinine elevation following fosinopril therapy (L), 382; switch in and indigent

Antibiotics, amikacin dosing in pediatric bronchopneum 749; colistin (A), 960; computer-assisted dose monitor (RR), 1026; erythromycin, pharmacoeconomics of intravenous therapy (RR), 669; methadone contamination (CR), 314; once-daily aminoglycosides for gram-positive endocarditis (A), 600; polymyxin B sulfate (A), 960

Anticonvulsant hypersensitivity syndrome, lamou

Antidepressants, pharmacoeconomic analysis (A), 365; tricyclic depressant use in diabetic neuropathy (A), 996 Antihypertensives, Alzheimer disease (A), 191; JNC V guideline

change impact on utilization in Department of Defen Antioxidants, Alzheimer disease treatment (A), 190

Antipsychotics, see Atypical Antipsychotics Antiretroviral agents, combination therapy (A), 198

Arthritis, analgesia and quality of life impact in elderly (RR), 1154; nsteroidal antiinflammatory drugs (A), 841

Aspirin, ACE inhibitor interactions (A), 375; management of acute coronary syndromes (A), 714

Asthma, montefukast, review (A), 1299; self-reported prevalence (NC), 133

itin, rhabdomyolysis induction with evelosporine (CR).

Atrial fibrillation, ibutilide (A), 38; digoxin, contemporary utilization (RR), 289

Atypical antipsychotics, No Mourning for the Co tipsychotics: The Dawn of Atypical Agents (O), 107; pharmacology, pharmacokinetics, and efficacy (A), 73

Autoinjector, bazards (L.), 751

erythromycin (A), 223, metronidazole (A), 223, doxyeveline (A), 223, cefoxitin (A), 223, probenecid (A), 223, amoxicillin/clavu nate (A), 223; cost (A), 225; dosage (A), 225; interactions (A), 224; pharmacokinetics (A), 219; pharmacology (A), 218; with clarithromycin, resistance (RR), 1262

Benzadiazepines, home treatment of acute seizures (A), 99 β-Blockers, Alzheimer disease treatment (A), 191; contraindica tions (A), 1066; nightmares (A), 93; myocardial infarction treat-

ment (A), 1063 Book reviews. Assessment and Treatment of Cancer Pain, Volume 12, 1128; BioBasics Series, 255; Contemporary Nutrition Support Practice: A Clinical Guide, 1129; The Death of Truth, 255; Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 1377 The Effects of Neurologic and Psychiatric Drugs on the Fetus and Nursing Infant, 1012; Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis, 1377; Introduction to Nutrition and Metabolism, Second Edition, 1012; Making Medical Decisions: An Approach to Clinical Decision Making for Practicing Physi-cians, 1128; Pharmaceutical Biotechnology: An Introduction for Pharmacists and Pharmaceutical Scientists, 119; Quality of Life and Pharmacoeconomics: An Introduction, 650; Sickle Cell Pain. 877; Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions, 119; Therapeutic Choices, Second Edition, 877

Books received, 120, 650, 878, 1013, 1378 nan, J Lyle, president, APhA (NC), 517

Brain tumor, clinical presentation (A), 817; etiology (A), 816; diagnosis (A), 817; pharmacotherapy for primary tumors (A), 818 Bransome, Edwin D Jr., president US Pharmacopeial Convention

Bromfenne, hepatotoxicity (CR), 945

Bromocriptine, chronic constrictive pericarditis induction (CR), 1050; compared with domperidone (A), 434 **Bupropion**, alopecia association (A), 633; serum sickn

tion (CR), 931; transient ischemic attack mimicking (CR), 305; ination therapy for treatment-res sion (CR), 701

Caffeine, schizophrenia effects (A), 484 Calcium, premenstrual syndrome (A), 1356 Calcitonin, phantom limb pain treatment (A), 499
Candesartan cilexetil, compared with amlodipine (A), 1294; enalapril (A), 1293, losartan (A), 1293; cost (A), 1295; pharma-

cokinetics (A), 1288; pharmacology (A), 1288; Carbamazepine, alopecia association (A), 633; compared with vagabatrin, seizure disorders (A), 1279; interaction, trazodone (L), 1370; interactions, severe multisystemic hypersensi (CR), 571; toxicity induction by fluconazole (CR), 790

Carbidopa, compared with domperidone (A), 434 Carboplatin, brain tumor therapy (A), 824

Cardiology, aminoglycosides once-daily for gram-positive endo carditis (A), 600; amlodipine dosing when converting from ni

ipine extended release for hypertension (RR), 7; β-blockers in myocardial infarction (A), 1063; Chlamydia pneumoniae and coronary heart disease (A), 615; community pharmacist interven-tion program effect on erum cholesterol risk (RR), 910; congestive heart failure patients, nonprescription medication use (RR), 674; dalteparin anticoagulation in mechanical heart valve patier (CR), 1188; digoxin, mutemporary utilization with atrial fibrillation (RR), 299; epoprosienol, primary pulmonary hypertension treatment (A), 340; glycoprotein IIb/IIa inhibitors in management of acute coronary syndromes (A), 712; ibutilide, arrhythmia treatment (A), 38; reieplase therapy (A), 318; troglitazone, cardiovas-cular effects (A), 229

Carter, Barry L. ACCP President-Elect (NC), 891 Cefepime, stability in peritoneal dialysis solution (RR), 906 Cefpodoxime, compared with trovafloxin, pneumonia (A), 55; armacokinetics, safety, tolerance of bolus or rapid infusion

Ceftriaxone, compared with trovafloxin, pneumonia (A), 55 Celecoxib, safety and effectiveness (A), 979 Chlamydia pneumoniae, coronary heart disease role (A), 615

Chloramphenicol, cyclosporine interaction (L.), 252; warfarin inter-action with ocular chloramphenicol (L.), 114

Cholinesterase inhibitors. Alzheimer disease (A), 182, 441 Christianity, ethics curriculum incorporation (A), 489 Chronic obstructive pulmonary disease, β-blocker contrain ns (A), 1067

Cidofovir, cytomegalovirus treatment (L.), 752; iritis induction

Cilastatin, see Imipenem/Cilastatin Cimetidine, effects on phenytoin con

(RR) 769 Ciprofloxacin, compared with trovafloxacin, pneumonia (A), 55;

phenytoin interactions (L), 251: rifampin interactions (A), 868 Cisapride, compared with domperidone (A), 434; rectal administra tion (A), 1217; syncopal episodes (L.), 251; torsade de pointes from clarithromycin interaction (CR), 22

Cisplatin, brain tumor therapy (A), 824 Citalopram, alopecia association (A), 633

Cladrithine, extravasion (L), 873 Clarithromycin, digoxin and warfarin interactions (CR), 796, (L), 1375; torsade de pointes from cisapride interaction (CR), 22; with azithromycin, resistance (RR), 1262

Clavulinie Acid, see Amoxicillin/clavulinie Acid Clindanycia, compared with trovafloxin, pneumonia (A), 55 Clinical trinls, alendronate (A), 593; anagrelide (A), 1117; , intravenous (A), 221; β-blockers in my farction (A), 1065; calcitonin in phantom limb pain (A), 500; candesartan cilexetil (A), 1291; carbamazepine, compared with viga-batrin, seizures (A), 1279; Chlamydia pneumoniae infection treatment and cardiovascular disease (A) 619; domperidone (A), 433; epoprostenol (A), 342; etidronate (A), 589; famotidine in schizophrenia (A), 742; fenofibrate (A), 1086; glutamine in catabolism (A), 350; ibutilide (A), 40; lamivudine (A), 1106; levodopa (A), 87; methylxanthine in anaphylaxis (A), 1002; montelukast (A), 1301; naratriptan (A), 70; nelfinavir mesylate (A), 328; nonsteroidal antiinflammatory drugs in Alzheimer disease (A), 844; omeprazole, extended-interval dosing in gastroesophage reflux disease (A), 638; once-daily aminoglycosides for gram-posi tive endocarditis (A), 603; reteplase (A), 320; ribavirin and respin ory syncytial virus, pneumonia treatment (A), 740; rifapentine (A), 1206; rotavirus, tetravalent vaccine (A), 834; sibutramine (A), 970 streptokinase for pleural effusion and epyerna (A), 4%, tolterodine (A), 1076; troglitazone (A), 229; trovafloxin (A), 54; urokinase for pleural effusion and epyema (A), 496; valproic acid in HIV pa (A). 1114; vigabatrin, compared with carbamezep

1279; vitamin E for tardive dyskinesia (A), 1196 Clofazimine, crystals in pulmonary macrophage cytoplasm (VO).

mine, treatment of obsessive-compulsive disorder elderly (CR), 686 Clonidine, Alzheimer disease treatment (A), 193

Clopidogrel, use with ticlopidine-induced hepatotoxicity (CR), 939 Clozapine, adverse effects, drug interactions, and costs (A), 210; neuroleptic malignant syndrome association (A), 623; (L), 1011 pharmacology, pharmacokinetics, and efficacy (A), 73; pleural effusion association (L), 1006, (L) 1374
Collistin, antibacterial spectrum (A), 961; chemistry (A), 961; clinical

es (A), 964; pharmacokinetics and dosing (A), 962; toxic 963; treatment for multiresistant gram-negative bacteria (A), 960

Comm. with acetaminophen overdose (CR), 1191 Compliance, antiretroviral agents (A), 464; critical evaluation erature methodology (RR), 531; noncompliance, Bell's palsy (CR), 1269; protease inhibitor therapy (RR), 899; sulfonylureas. sance organization (RR), 281

Computers, ABBOTTBASE calculation error (L), 1230; antibi dose monitoring (RR), 1026; compliance, critical evaluation of literature methodology (RR), 531; electronic data, risk factor deter-mination (RR), 406; JNC V guideline change impact on antihyper tensive utilization in Department of Defense database (RR), 548 Concentrations, cirretidine effects on phenytoin (RR), 769; dilti-

azem effect on tacrolimus (CR), 680: itraconuzole effects on acrolimus blood concentrations (L.), 1124; methotrexate (CR) 952, rifampin effects on cyclosporine (L), 871, vancomycin, endstage renal disease (L), 116

Congestive heart failure, ACE inhibitor-as ontinuous venovenous hemofiltration, propalenone disposition (CR), 957

orticostervids, allergic-type reactions (A), 451; brain turnor sup-portive therapy (A), 818; compared with montelukast (A), 1307 Cost, see Plan

Crane, Vicki S, APhA Distinguished Achievement Award in Hospital and Institutional Practice (NC), 135

Creatinine, elevation following fosinopol therapy (L.), 382
Creatine kinase, chronic elevation not associated with HMG-CoA reductase inhibitor treatment (CR), 163; serum elevation follow ing olanzapine therapy (CR), 697

Cyclooxygennse-2 inhibitors, costs (A), 986; phan 980; safety and effectiveness (A), 979; types (A), 981 Cyclosporine, chloramphenicol interaction (L), 252; encephalopa

thy induction (L.), 750; rhabdomyolysis induction tatin (CR), 1176; rifampin interactions (L.), 871

cann C.S., 171-6, manufus interactions (E.), 671. Cystic fibrowine, pyloric channel stricture scoondary to high-dose ibuprofen therapy (CR), 693. Cytarubine, brain tumor therapy (A), 825: pseudotumor cerebri secondary to intermediate dose (CR), 576.

Cytomegalovirus, antiinfectives update (A), 609; cidofovir treat-

D-E

Dulteparin, anticoagulation in mechanical heart valve patient (CR),

ne, ocular toxicity (L), 505 Dementia, see Alzheimer disease; Huma

virus Depression, tricyclic antidepressant use is diabetic nephropathy (A), 996; venlafaxine with bupropion for treatment-resistant depression (CR), 701

Dermatitis, trovafloxacin and exfoliative dermatitis (VO), 1122 Desigramine, alonecia association (A), 632 nethusone, headache, manag

Dexfenflurumine, comparison with sibutramine (A), 974 Dexrasocane-CHOP therapy, cutaneous and subci sis (1.), 253

Dextromethorphon, diabetic neuropathy treatment (A), 122 Diabetes mellitus, home blood glucose monitoring (A), 355; β-blocker contraindications (A), 1068; type 1, angiotensin-conv ing enzyme polymorphism and diabetic nephropathy (A), 474, type 2, troglitazone, cardiovascular effects(A), 229 Diabetic gastroparesis, domperidone therapy (A), 433

Diabetic neuropathy, dextromethorphan treatment (A), 1221 Diabetic nephropathy, angiotensin-converting enzyme polyn phism and type I diabetic nephropathy (A), 474; tricyclic antide pressant use (A), 996

Diaphoresis, association with extended release venlafaxine (L), 1009 Digoxin, clarithromycin interactions (CR), 796; contemporary utilization with atrial fibrillation (RR), 289

Dihydroergotamine, headache, ma duced (A), 67

Diltiazem, tacrolimus interactions (CR), 680 Dobutamine, β-adrenergic antagonist selectivity at low doses of carvedilol (CR), 1266

Domperidone, adverse effects (A), 435; compared with bromocrip tine, carbidopa, levodopa, metoclopramide (A), 434; interactions (A), 436; pharmacodynamics (A), 431; pharmacokinetics (A), 432; pharmacology (A), 430

Donepezik, Alzheimer diser ent (A), 182; (CR), 443; over dose (CR), 812

Dong, Betty J. ACCP Regent (NC), 891

Dopannine D₂ receptor, modulation in schizophrenia (A), 480 Dosing, amilacin in pediatric bronchopneumonia (L.), 749; amino-glycosides for gram-positive endocarditis (A), 600; amlodipine in conversion from extended-release nifedinine (RR), 7: anagrelide (A), 1117; azithromycin, intravenous (A), 225; cefepime, bolus or rapid infusion (RR), 1258; domperidone (A), 436; donepezil overdose (CR), 812; fenofibrate (A), 1098; nelfinavir mesylate (A), 331, 335; olanzapine for schizophrenia (L), 1228; omeprazole, extended-interval dosing in gastroesophageal reflux diseas (A), 638; phenobarbital, neonate receiving extracorporeal membrane oxygenation (CR), 419; polymyxins (A), 962; reteplase (A), 319; rifapentine (A), 1207; ritonavir regimens, discontinution rates (RR), 899; sibutramine (A), 968

Doxepin, adverse effects in breast feeding (CR), 690; pharmacoeconomic analysis (A), 368

Doxycycline, methotrexate interactions (CR), 804 ation, economic impact of drug information service

Drug Information Rounds, ACE inhibitor-aspirin interactions (A), 375; albuterol for treatment of hyperkalemia (A), 103; anagrelide for thrombocytosis treatment (A), 1116; benzodi treatment of acute seizures (A), 99; calcitonin in phantom linb pain (A), 499; calcium for premenstrual syndrome (A), 1356; cisapride, roctal (A), 1217; dextromethorphan for diabetic neuropathy (A), 1221; HMG-Coa reductase inhibitors in children (A), 1224; lamotrigine for mood stabilization (A), 864; latex allergy risk from medication vial closures (A), 373; methylxanthine use in anaphylaxis (A), 1001; omeprazole and vitamin B₁₂ deficiency (A), 641; omeprazole dosing in gastroesophageal reflux e (A), 638; osteoporosis treati ment in chronic liver di (A), 233; respiratory syncytial virus pneumonia treatment (A), 739: streptokinase versus urokinase for treatment of pleural effusions and empyemas (A). 495; tricyclic antidepressant use in diahetic nephropathy (A), 996; troglitazone, cardiovascular effects (A), 229; valproic acid in HIV patients (A), 1113 Drug interactions.

ACE inhibitors—aspirin (A), 375 acenocoumarol—acetaminophen (L), 506 acenocoumarol-miconazole oral gel (CR), 175 minorhen-acenocoumarol (L), 506

anticonvulsants, risk in HIV-positive putients (L), 1373 antiretroviral-psychotropic drugs (A), 461, (L), 1372 aspirin-ACE inhibitors (A), 375 atoryastatin-cyclosnorine (CR), 1176 atypical antipsychotics (A), 210 carbamazepine-fluconazole (CR), 790 carbamazepine-trazodone (L), 1370 carvedilol-dobutamine (CR), 1266 chloramphenicol-cyclosporine (L), 252 chloramphenicol, ocular cimetidine-phenytoin (RR), 769 ciprofloxacin-phenytoin (L), 251 ciprofloxacin-rifampin (A), 868 clarithromycin-cisapride (CR), 22 clarithromycin-digoxin (CR), 796 clarithromycin-warfarin (CR), 796 cyclosporine-atorvastatin (CR), 1176 cyclosporine-chloramphenicol (L), 252 cyclosporine-diltiazem (L), 750 cyclosporine-rifampin (L), 871 digoxin-clarithromycin (CR), 796 diltiazem-evclosporine (L), 750 diltiazem-tacrolimus (CR), 680 dobutamine-carvedilol (CR), 1266 domneridone, review (A) 436 doxycycline-methotrexate (CR), 804 fluconazole-carbamazepine (CR), 790 green tea-warfarin (CR), 426 levodopa-tolcapone (L), 1228 methotrexate-doxycycline (CR), 804 miconazole oral gel-acenocoumarol (CR), 175 nefazodone-pravastatin (L), 871 nelfinavir mesylate, review (A), 332 phenytoin-cimetidine (RR), 769 phenytoin-ciprofloxacin (L), 251 prayastatin-pefazodone (L) 871 psychotropic drug-antiretroviral interactions (A), 461, (L), 1372 rifampin-ciprofloxacin (A), 868 rifampin-cyclosporine (L), 871 St. John's wort-theophylline (L), 502 tacrolimus-itraconazole (L), 1124 tacrolimus-dilatiazem (CR), 680 theophylline-St. John's wort (L.), 502 tolcapone-levodopa (L), 1220 tolte-odine-warfarin (CR), 1173 trovafloxacin, review (A), 50 trazodone-carhamazepine (L), 1370 vigabatrin, review (A), 1283 warfarin-clarithromycin (CR), 796 warfarin-green tea (CR), 426

warfarin-tolterodine (CR), 1173 Drug selection perspectives. porosis treatment (A), 587

warfarin-ocular chloramphenicol (L), 114

Drug utilization, over-the-counter prescribing patterns (RR), 400 Dyserythropoietic anemia, carbamazeoine induction (CR), 57!

Dyspepsia, domperidone therapy (A), 435 Dystonia, induction by fluvoxamine and metoclopramide (L), 382 Editorials, see also Opinions, Pediatric Drug Formulations: Challenges and Potential Solutions (E), 247

Education. Ethics in Christianity and Health Care course (A), 489; interdisciplinary mock trial (A), 850, 1388 Educational Events. 127, 269, 393, 514, 661, 760, 886, 1019.

Electronic pharmacy data, drug-related risk identification (RR), 406 Empyemas, streptokinase versus urokinase for treatment (A), 495 Enalapril, compared with candesartan cilexetil (A), 1293 End-stage renal disease, vancomycin concentr

Endocarditis, aminoglycosides once-daily for gram-positive endo-

Endocrinology, compliance with sulfonylureas, health maintenance rganization (RR), 281

Epidemiology, medication-induced headache (A), 62

Epilepsy, vigabatrin (A), (277 Epoprostenol, adverse reactions (A), 345; clinical trials (A), 342; pharmacology (A), 342; primary pulmonary hypertension treat-ment (A), 340

Eptifibatide, management of acute coronary syndromes (A), 717 Ergoloids, Alzheimer disease treatment (A), 194 Erythema multiforme, amoxicillin/clavulinic acid induction (VO).

109; phenytoin induction (VO), 748 Erythromycin, compared with trovafloxacin, pneu nonia (A), 55; intravenous, clinical and financial impact (L), 1371; pha coeconomics of intravenous therapy (RR), 669; Stevens ens-Johnson syndrome (VO), 1369

sophagitis, oral rifampin induction (CR), 27 Estrogen, Alzheimer disease treatment (A), 180; dementia-related on treatment in men (CR), 808; replacement therapy (A),

Ethics, education (A), 489; interdisciplinary mock trial (A), 850 Etidronate, clinical trials (A), 589; compared with alendronate (A) 596; conts (A), 596; pharmacokinetics (A), 589; pharmacology (A), 588; osteoporosis treatment (A), 587; safety (A), 596

Etoponide, brain turnor therapy (A), 825; pharmacokine Ette, Ene I. ACCP Russell R Miller Award (NC), 1022 etics (L), 115 EUK-8. Alzheimer disease treatment (A), 191 Extracorporent membrane oxygen 416: phenobarbitol dosing and pharmacokinetics (CR), 419

F-H

Famotidine, management of schizophrenia (A), 742 Fenofibrate, micronized, chemistry (A), 1084; clinical trials (A), 1086; costs (A), 1097; dosing (A), 1098; hyperlipidemia management (A), 1083; interactions (A), 1092; pharmacodynamics (A), 1085; pharmacokinetics (A), 1085; pharmacology (A), 1084. safety (A), 1086

Fluconagole carbam Fluorsetine, alopecia association (A), 632; Japan, legal problems (L), 752; pharmacoeconomic analysis (A), 368

Fluvoxamine, acute dystonia induction with metoclopramide (L),

382; alopecia association (A), 632
Follow-up, phone call impact in Medicaid drug utilization program /RR) 541

Formulary Forum, azithromycin, intravenous (A), 218; cande tan cilexetil (A), 1287; domperidone (A), 429; fenofibrate (A), 1083; ibutilide (A), 38; montelukast (A), 1299; naratriptan (A), 704, nelfinavir mesylate (A), 325; reteplase (A), 318; rifapentine tuberculosis treatment (A), 1203; sibutramine (A), 968; toltero dine for overactive bladder (A), 1073; trovafloxacin (A), 48; vigabatrin (A), 1277

Fosinopril, creatinine elevation following therapy (L), 382; pharma cokinetics with hydrochlorothiazide (RR), 525

Gabapentin, alopecia association (A), 634 Galantamine, Alzheimer disease therapy (A), 446

Gastroesophageal reflux disease, domperidone therapy (A), 435. omeprazole dosing (A), 638; quality of life in patients (RR), 1032

neral medicine, estrogen replacement therapy, raloxifene (A), 1315; gastroesophageal reflux disease and quality of life (RR). guideline changes and Department of Defense Database (A), 548; medication-related visits to the emergency department

Genetics, Alzheimer disease research (A), 179 tamicin, inadvertent epidural administration (L), 1123

Geriatrics and gerontology, adverse drug events in elderly receiv-ing home health services (RR), 1147; Alzheimer disease, see Alzheimer Disease; medication use in residential care facilities for the elderly (RR), 149; obsessive-compulsive disorder, clomi pramine treatment in the elderly (CR), 686; osteoarthritis analgesia and quality of life impact (RR), 1154

Glucose, home blood monitoring (A), 355 tion in catabolic patients (A), 348 Glycoprotein Hb/Ha inhibitors, management of acute coronary

Gout, alloparinol desensitization (CR), 1180 Granulocytopenía, nifuroxazide association (L), 1229 Green tea, warfarin interactions (CR), 426 Guanfacine, Alzheimer disease treatment (A), 193

Haemophilus influenzae, elimination of type b disease (NC), 134 Hair loss, see Alopecia

Haloperidol, torsade de pointes induction (CR), 1046 Headache, medication-induced, management (A), 61 Health maintenance organization, compliance with sulfonylureas

Hemodialysis, levodopa management of restless legs syndrome in hemodialysis population (A), 86

Hepatitis A, vaccination (A), 612 Hepatitis B, lamivudine treatment of chronic infection (A), 1104;

vaccine without thimerosal (NC), 1242 Hepatotoxicity, amoxicillin/clavulinic acid (CR), 560; amphotericin B (CR), 683; bromfenac (CR), 945; oxaprozin (CR), 943; quinine (CR), 32; sertraline and venlafaxine (L), 381; ticlopidine (CR), 939 Herbs, safety (A), 1359

Herpes simplex virus, antiinfectives up late (A), 610 HMG-CoA reductase inhibitors, see Hydroxymethylglutaryl

coenzyme A reductase inhibitors

Hormonal therapy, Alzheimer disease (A), 180 Human immunodeficiency virus, amiodarone in serum, effects of antiretroviral therapy (L), 645; antiinfectives update (A), 607; antiretroviral-psychotropic drug interactions (A), 461; antiretr therapy, pharmacologic considerations for success (A), 989; eido fovir, iritis induction (CR), 167; combination antiretroviral therapy (A), 198; hepatic lesions from trimethoprim/sulfamethoxaz (L), 1007; hyperlipidemia with protease inhibitor therapy (A), 859; indinavir-associated rash (RR), 17; nelfinavir mesylate th pv (A), 325; nonprescription and alternative medication use (RR), 294; opportunistic illnesses (NC), 761; pentamidine-induced hemolytic anemia (L), 503; perinatal prevention (NC), 396; post exposure prophylaxis registry (L), 516; protease inhibitor dosing and compliance (RR), 899; riluzole therapy for demenita (L), 114; Stevens-Johnson syndrome induced by sulfadiazine (L), 379 trimethoprim/sulfamethoxazole, failure in *Pneumocystis caria* pneumonia treatment (CR), 413; valproic acid use (A), 1113 Hydrochlorothiazide, pharmacokinetics with fosinopril (RR), 525;

pulmonary edema induction (CR), 172; (L), 1010 Hydroxymethylglutaryi coenzyme A reductase inhil

tine kinase elevation not associated with treatment (CR), 163; pe-diatric hypercholesterolemia treatment (A), 1224

Hydroxyurea, brain tumor therapy (A), 826 Hyperkalemia, albuterol treatment (A), 103

Hyperlipidemia, fenofibrate management (A), 1083; pediatric hypercholesterolemia treatment with HMG-CoA reductase inhibitors (A), 1224; protease inhibitor therapy induction (A), 859

Hypertension, amlodipine dosing when converting from nifedipin

ended release (RR), 7; primary pulmonary, epoprostenol (A), 340; uncontrolled, noncompliance produces Bell's pulsy (CR),

I-L

re secondary to high-done therapy in cystic fibrosis (CR), 693

Ibutilide, adverse reactions (A), 43; arrhythmia to compared with procainamide (A), 40; sotalol (A), 40; cost (A), 44: pharmacokinetics (A), 40; pharmacology (A), 39 Imipenem/cilustatin, cost-minimization analysis (RR), 156

Impromine, alonecia association (A), 632

nmune globulin intravenous, availability for treatment of im-mune deficient patients (NC), 515; renal failure after large doses (CR), 800; Wegener's granulomatosis treatment (CR), 1055 nmunization, childhood, CDC recommendations (NC), 270

Indinavir, anti-HIV therapy (A), 201; rash association (RR), 17 Infectious diseases, antibiotic dose monitor, computer-assisted

(RR), 1026; antiretroviral agents, pharmacologic consideration for success (A), 989, psychotropic drug interacti azithromycin, with clarithromycin, resistance (RR), 1262; cefepime stability in peritoneal dialysis solution (RR), 906, pharma-cokinetics, safety, tolerance of bolus or rapid infusion (RR), 1258. clarithromycin, with azithromycin, resistance (RR), 1262; colist (A), 960; HIV, combination antiviral therapy (A), 198, nonpre-scription and alternative medication (RR), 294; hyperlipidemia with protease inhibitor therapy (A), 859; lamivudine for chronic hepatitis B (A), 1104; Lyme disease prevention and prophylaxis (A), 723; piperacillin/tazobactam vs. imipenem/cilastatin, cost minimization (RR), 156; polymyxin B sulfate (A), 960; ritonavir discontinuation rates (RR), 899

Influenza virus, activity (NC), 395, 516, 1389; pre trol (NC), 889

Interferon alpha-2a, photosensitive seizures (L), 113 International normalized ratio, diarrhea association with elevation in patient on warfarin (CR), 301

ternational Reports, Iran, adverse drug reactions (IR), 236 Irinotecan, brain turnor therapy (A), 826
Iritis, cidofovir induction (CR), 167

Isoniazid, induced psychosis, pyridox Itraconazole, tacrolimus interactions (L.), 1124

Japan, legal problems with fluoxetine use (L.), 752

Lamivudine, adverse effects (A), 1109; clinical trials (A), 1106; comparison with nelfinavir mesylate (A), 329; hepatitis B, treat-ment of chronic infection (A), 1104; resistance (A), 1109 Lamotrigine, mood stabilization (A), 864; overdo

anticonvulsant hypersensitivity syndrome (CR), 557; skin rash, factors influencing (RR), 1037

Latex Allergy, risk from medication vial closures (A), 373

Law, pharmacy practice acts (RR), 920 Levodopa, management of restless legs syndrome in hemodialysis population (A), 86; vitiligo association (L), 1228 Levofloxacin, Achilles tendonitis induction (CR), 792

Lithium, alopecia association (A), 633 Liver transplant, osteoporosis treatment in chr

Losartan, angioedema (CR), 933 (CR), 936; compared with canartan cilexetil (A), 1293

Lyme Disease, epidemiology (A), 723; presentation (A), 724; prevention and vaccination (A), 723; vaccine availability (NC), 395

M-O

Mania, risperidone induction (L.), 380

Medication errors, antibiotics, methadone contamination (CR). 314; donepezil overdose (CR), 812; gentamicin, inadverti epidural administration (L), 1123; pregnancy outcome following pinaverium exposure (L), 112 Medication-induced headache, see Headache, medication-in-

Melanoma, treatment of malignant disease (A), 730 Meloxicam, safety and effectiveness (A), 979

Mesopouse, estrogen replacement therapy and raloxifene (A), 1315 Metabolic acidosis, with acetaminophen overdose (CR), 1191 Methadone, antibiotic contamination (CR), 314; (L), 101 Methicillin-resistant Staphylococcus aureus, pediatric deaths from strains (NC), 1136

Methotrexate, acral erythema from high-dose infusion (L), 646; brain turnor therapy (A), 825; dose-related increases in cere-brospinal fluid (CR), 952; doxycycline interactions (CR), 804 Methylergonovine, headache, management of medication-induced

Methylxanthine, use in anaphylaxis (A), 1001

Metoclopramide, acute dystonia induction with fluvoxamine (L. 382; compared with domperidone (A), 434; neuroleptic maligr with fluvoxamine (L) syndrome association (L), 644; reversible nonthrombocytopenic lpable purpura (CR), 35

Metrifonate, Alzheimer disease therapy (A), 445 Metronidazole, compared with trovafloxacin, pnes Miconazole, oral gel interactions with acenocoumarol (CR), 175 Mifepristone, brain tumor therapy (A), 827 Migraine, naratriptan treatment (A), 704

Milnaciprun, Raynaud's syndrome association (L), 1009

Mitolactol, brain tumor therapy (A), 826

Mock Trial, education (A), 850 Montehakast, adverse reactions (A), 1307; compared with inhaled corticosteroids (A), 1307; drug interactions (A), 1308; pediatri-(A), 1304; pharmacokinetics (A), 1301; pharmacokinetics (A Mycobacterium avium complex, antiinfectives update (A), 609

Mycones, antiinfectives update (A), 611 Myocardial infarction, reteplase (A), 318

Nahata, Milap C, APhA Research Achievement Award (NC), 271; President-elect canddate, AACP

tion (CR), 317 Nappi, Jean M. President-elect candidate, AACP

Naratriptan, adverse effects and interactions (A), 708; comparison with other triptans (A), 707; costs (A), 709; migraine treatment (A), 704; pharmacodynamics (A), 705; pharmacokinetics (A), 705; toxicology (A), 706; clinical trials (A), 706 scrools, oxacillin induction (CR), 1060

Nefazodone, pravastatin interactions (L), 871

Neffinavir mesylate, adverse reactions (A), 331; anti-HIV therapy (A), 202, (A), 325; compared with larmyudine (A), 329, stavudine (A), 329, zidovudine (A), 329; cost (A), 336; dosing (A), 330, 335; interactions (A), 332; pharmacokinetics (A), 327; pharmacokinetics (A), 327; pharmacokinetics (A), 327; pharmacokinetics (A), 327; pharmacokinetics (A), 328; pharmacokinetics (A), 328; pharmacokinetics (A), 329; pharma macology (A), 326

Nephrology, angioten (A), 474; intravenous immune globulin and acute renal failure (CR), 800; levodopa management of restless legs syndrome in hemodialysis population (A), 86; tricyclic antidepressant use in diabetic nephropathy (A), 996; end-stage renal disease (L), 116, (A), 1329

Nerve growth factor, Alzheimer disease treatr Neurobiologies, Alzheimer disease (A), 183

Neuroleptic malignant syndrome, clozapine asso (L), 1011; metoclopramide association (L), 644

Neurology, headache, management of medication-induced (A), 61; lamotrigine-related skin rash, factors influencing (RR), 1037; vitamin E, tardive dyskinesia treatment (A), 1195 New publications, see Book Reviews

Nifedipine, amlodipine dosing when contended release (RR), 7

Nifurovazide, granulocytonenia association (L.), 1229 Nightmares, drug-induced, literature review (A), 93 Nimodipine. Alzheimer disease treatment (A), 193 Nitrogen mustards, brain tumor therapy (A), 821 Nitrosourens, brain tumor therapy (A), 822

Nonprescription medication, congestive heart failure patient use (RR), 674; green tea inhibition of warfarin (CR), 426; HIV patient use (RR) 794

teroidal antiinflammatory drugs. Alzheimer diss

(A), 840; bromfenac hepatotoxicity (CR), 945; cyclooxygenase-2 nhibitors (A), 979; headache, management of medication-induced (A), 65 Nootropics, Alzheimer disease treatment (A), 183 Nucleoside analog reverse transcriptase inhibitors, co

therapy in HIV (A), 199 Obesity, sibutramine tr

Obsessive-compulsive disorder, clomipramine treatment in the el-

Ocular Toxicity, deferovamine (L.), 505 Olanzapine, adverse effects, drug interactions, and costs (A), 210; creatine kinase serum elevation following therapy (CR), 697; pharmacology, pharmacokinetics, and efficacy (A), 73; schizophrenia, high-dose therapy (L), 1228; seizure induction

(CR), 554; status epilepticus-associated fatality (CR), 787 Omeprazole, dosing in gastroesophageal reflux disease (A), 638;

vitamin B₁₂ deficiency (A), 641 Oncology, brain tumor treatment (A), 816; malignant melanoma treatment (A), 730

Onycholysis, association with weekly administration of paclitaxel (CR), 584

Opinions, see also Editorials, No Mourning for the Co Antipsychotics: The Dawn of Atypical Agents (O), 107 Opioids, sedation, amphetamine use (A), 1362

Orthostatic hypotension, oral vasopressors in ma Osteoporosis, etidronate and alendronate in trea mt (A), 587:

treatment in chronic liver disease patients (A), 233 Ototoxicity, vinblastine (CR), 423

Over-the-counter drugs, prescribing patt Oxacillin, necrosis induction (CR), 1060 Oxunrozin, henatotoxicity (CR), 943 Oxybutynin, comparison with tolte

Paclitaxel, brain tumor therapy (A), 827; compatibility with ethy lene vinyl acetate bags (L), 873; onycholysis with weekly adminstration (CR), 584

Parkinson's disease, bromocriptine, chronic constrictive peri tis induction (CR), 1050; domperidone adjunct therapy (A), 433;

vitiligo, talcapone and levodopa association (L), 1228

Paroxetine, alopecia association (A), 632; pharmacoeco ysis (A), 366

Patterson, J Herbert, ACCP Secretary (NC), 891 Pediatrics, albuterol delivery systems for infants (RR), 141; al-teplase treatment in extracorporeal membrane oxygenation (CR), 416: amikacin dosing for bronchopneumonia (L), 749; hyperc-holesterolemia treatment with HMG-CoA reductase inhibitors (A), 1224; montehikast, asthma (A), 1304; nebulized versus me-tered-dose inhalers for infants (RR), 144; Pediatric Drug Formulations: Challenges and Potential Solutions (E), 247; phenobarbitol dosing and pharmacokinetics (CR), 419; rotavaccine (A), 833; valproate therapy for status epilepticus (CR), 579; vigabatrin for seizures (A), 1280

Pentamidine, induced hemolytic anemia in AIDS (L), 503 Pericarditis, bromocriptine, chronic constrictive peric tion (CR), 1050

Peritoneal dislysis, cefepine stability in solution (RR), 906 Phantom limb pain, calcitonin treatment (A), 499
PharmaCE, order form, 126, 258, 388, 508, 654, 758, 882, 1018, 1234, 1380; questions, 123, 259, 389, 511, 655, 755, 883, 1015,

Pharmacodynamics, domperidone (A), 431; fenofibrate (A), 1085; rifapentine (A), 1204; tolterodine (A), 1075

Pharmacoeconomics, amlopidine vs. extended-release nifedipine (RR), 9; antidepressant therapy analysis (A), 364; atypical an tipsychotics (A), 210; azithromycin (A), 225; bisphosphonate rapy (A), 596; candesartan cilexetil (A), 1295; cyclooxyge nase-2 inhibitors (A), 986; drug information service, or impact (RR), 11; erythromycin, intravenous therapy (RR), 669; fenofibrate (A), 1097; ibutilide (A), 44; macrolides in lower res ratory tract infection treatment (L), 1125; naratriptan (A), 709; ratory tract intection treatment (L.). Italy narastipan (A), 70%, neoffmaxir mexplate (A), 336; piperacillin/razobactam versus spen-ent/cilastatin (RR), 156; retepfase (A), 323; rifapentine (A), 1208; risperidone in outpatient populations (RR), 1160; rotavirus, tetravalent vaccine (A), 836; sibutramine (A), 976; trovafloxacin (A), 56: vigabatrin (A), 1283

harmacoepidemiology, risk factor estimation for drug-related problems (RR), 406

promise (sex). «on the promise (A), 464; (A), 990; atypical antipsychotics (A), 75; azithromycin, intravenous (A), 219; candesartan cilexeli (A), 1288; cefepine (RR), 1288; ciprofloxacin—frampin (A), 880; colistin (A), 962; domperidone (A), 432; doxycylcine—methotrexate (CR), 805; etoposide (L), 115; fenofibrate (A), 1085; fosinopril and hydrochlorothiazide (RR), 525; ibutilide (A), 40; methotrexate in cerebrospinal fluid (CR), 952; methotrexate-doxycylcine (CR), 805; nelfinavir me sylate (A), 327; phenobe-bitol in extracorporeal membrane ox-genation (CR), 419; phenytoin, rectal (RR), 781; polymyxin B sulfate (A), 962; reteplase (A), 320; rifampin-ciprofloxacin (A), 868; rifapentine (A), 1204; sibutramine (A), 970; tolterodine (A),

1075; trovafloxacin (A), 49; vigabatrin (A), 1278

Pharmacology, anagrelide (A), 1117; azithromycin, intravenous (, 218; bisphosphonates (A), 588; candesartan cilexetil (A), 1288; clozapine (A), 74; cyclooxygenase-2 inhibitors (A), 980; dompen done (A), 430; epoprostenol (A), 342; fenofibrate (A), 1084; ibutilide (A), 39; naratriptan (A), 705; nelfinavir mesylate (A), 326; olanzapine (A), 76; quetiapine (A), 77; reteplase (A), 318; rifapentine (A), 1203; risperidone (A), 76; sibutramine (A), 969; tolero-dine (A), 1074; trovafloxacin (A), 49; vigabatrin (A), 1278 Pharmacy practice acts, overview of states (RR), 920

perfuse area, overview of states (RR), 920 pelps, Stephanie J, Outstanding APhA-ASP Chapter Advisor Award (NC), 396

Phenobarbitol, dosing and pharmacokinetics in extracorporeal ne oxygenation (CR), 419

Phenyl-tert-butyl nitrone, Alzheimer disease treatment (A), 191 henytoin, cimetidine effects on concentrations in seizure patien (RR), 769; ciprofloxacin interactions (L), 251; crythema multiforme induction (VO), 748; potential underreportir events (L), 111; rectal pharmacokinetics (RR), 781

events (L), 111; cacta paramasounces (RK), 761
Photosensitive seizure, see Seizure
Physostigmine, Alzheimer disease therapy (A), 444
Pinaverium, pregnancy outcome following exposure (L), 112
Piperaceillinzbanctum, cost-minimization analysis (RR), 156
Piracetam, headache, management of medication-induced (A), 68 Pleural effusion, clozapine association (L), 1008; streptokinase versus urokinase for treatment (A), 495

Pneumocystis carinii Pneumonia, trimethoprim/sulfamethoxazole ent (CR), 413 iology (A), 1212; valproate

Polycystic ovary syndrome, cpi

ion (A), 1211 Polymyxim B sulfate, antibacterial spectrum (A), 961; chemistry (A), 961; clinical uses (A), 964; pharmacokinetics and dosing

(A), 962; toxicity (A), 963; treatment for multiresi ative bacteria (A), 960

Pravastatin, nefazodone interactions (L), 871
Pregnancy, dosepin, adverse effects in breast feeding (CR), 690; fenofibrate safety (A), 1097; outcome following pinas posure (L), 112; pinaverium dispensing error (L), 112 Prescribing, over-the-counter (RR), 400

ide, compared with ibutilide (A), 40; induced psychosis (CR), 948

Procarbazine, brain tumor therapy (A), 823

Propulenome, disposition during continuous venovenous hemofil-tration (CR), 957

Protamine, noncardiogenic pulmonary edema induction (CR), 927 Proteuse inhibitors, combination therapy in HIV (A), 199; hyper lipidemia (A), 859; psychotropic drug interactions (A), 461; rits avir regimens, discontinuation rates (RR), 890

Prothipendyl, headache, management of medication-induced Prothrombin Time, handheld monitoring devices (RR), 775 Provitos, association with extended-release venlafaxine (L.), 1009

mor cerebri, secondary to intermediate-dose cyta

tiretroviral-psychotropic drug interactions (A), 461; atypical an tipsychotics, adverse effects, drug interactions, and costs (A), 210; atypical antipsychotics, pharmacology, pharmacokinetics, and efficacy (A), 73; clossipsyamine treatment of obsessive-compulsive disorder elderly (CR), 686; clozapine, neuroleptic malignant syr drome association (A), 623; dopamine D, receptor modulation in ement of schizophreni schizophrenia (A), 480: famotidine man schizopremia (A), 480; Tamodalne management of schizophremia (A), 742; isonizard-induced psychosis, psylodosis in effectiveness (L), 1123; procainamide-induced psychosis (CR), 948; risperidone-induced mania (L), 380; risperidone, pharmacoeconomics in compatient populations (RR), 1160; risycle: antidepressant use in compatient populations (RR). diabetic nephropathy (A), 596; vendatanie with hopropion for treatment existant depression (CR), 701

Pulmonary edema, hydrochlorothiazide induction (CR), 172; (L),

1010; protamine induction (CR), 927

Purpura, metoclopramide association with reversible nonthrombocytopenic palpable purpura (CR), 35

Q-S

Quality of life, gastroesophageal reflux disease patients (RR), 1032; osteoarthritis analgesia and quality of life impact in elderly (RR), 1154; pharmacist intervention impact (RR), 1167

huetiapine, adverse effects, drug interactions, and costs (A), 210; pharmacology, pharmacokinetics, and efficacy (A), 73

Quínine, hepatotoxicity (CR), 32
Raloxifene, adverse effects (A), 1324; clinical trials (A), 1323; osteoporosis, cardiovascular disease, gynecologic cancers (A), 315; pharmacokinetics (A), 1323; pharmacology (A), 1322
Raynaud's Syndrome, milnacipran association (L), 1009
Residential care facilities for the elderly, medication use (RR), 149

Respiratory syncytial virus, activity (NC), 133; pneum ment (A), 739

Restless legs syndrome, levodopa management in hemodialysis population (A), 86
Reteplase, adverse reactions (A), 320; compared with alteplase.

streptokinase (A), 320; cost (A), 323; dosage (A), 319; pharma-cokinetics (A), 320; pharmacology (A), 319 Reynaud's phenomenon, β-blocker contraindications (A), 1068

Rhabdomyolysis, atorvastatin with cyclosporine induction (CR), 1176; naltrexone association (CR), 312

Rho Chi Lecture, pharmaceutical sciences in the next mille Ribavirin, respiratory syncytial virus, pner

Rifampin, ciprofloxacin interactions (A), 868; cyclosporine interactions (L), 871; esophagitis induction from pills (CR), 27
Rifapentine, chemistry (A), 1203; clinical trials (A), 1206; costs (A), 1208; dosing (A), 1207; interactions (A), 1207; pharmacokinetics (A), 1204; pharmacodynamics (A), 1204; pharmacology

(A), 1203; safety (A), 1206; tuberculosis treatment (A), 1203 Rihuzole, HIV demenita therapy (L), 114 Risperidone, adverse effects, drug interactions, and costs (A), 210; ania induction (L), 380; pharmacoeconomics in outpatient pop lations (RR), 1160; pharmacology, pharmacokinetics, and effi-

Ritonavir, anti-HIV therapy (A), 201; saquinavir combination ther-

apy (RR), 899

Rivastigmine, Alzheimer disease therapy (A), 445 Rofecoxib, safety and effectiveness (A), 979

Rotavirus, intussusception among vaccine recipients (NC), 1020; tetravalent vaccine (A), 833

Rush, David R. ACCP Regent (NC), 891
Sagraves, Rosalie. president, American Pharmaceutical Assi Academy of Pharmaceutical Research and Science (NC), 135 St. John's Wort, theophylline interactions (A), 502

Saquinavir, anti-HIV therapy (A), 201; dosing and ritonavir combiation therapy (RR), 899

Schizophrenia, dopamine D₂ receptor modulation (A), 480; famoti-dine management (A), 742; olanzapine, high-dose therapy (L),

Schwingammer, Terrence L. APhA-APPM Distinguished

Achievement Award (NC), 271

Scott, Ginger G, PharmaCE educational consultant (NC), 762

SCRIP, see Study of Cardiovascular Risk Intervention by Phar-

Sedative/hypnotics, nightmares (A), 93

Seizure, benzodiazepines in home treatment of acute se- cimetidine effects on phenytoin concentrations (RR), 769; it terferon alpha-2a induction of photosensitive seizures (L), 113; olanzapine induction (CR), 554

Selective serotonin reuptake inhibitors, alopecia asse 632; headache, management of medication-induced (A), 68; pharmacoeconomic analysis (A), 368
Serenics, Alzheimer disease treatment (A), 180

Sertindole, adverse effects, drug interactions, and costs (A), 210; pharmacology, pharmacokinetics, and efficacy (A), 73

Sertraline, alopecia association (A), 633, liver darrage with venlafaxine (L), 381; pharmacoeconomic analysis (A), 368 Serum Sickness, bupropion association (CR), 931

Sibutramine, adverse effects (A), 974; comparison with dexfenfluramine (A), 974; clinical trials (A), 970; costs (A), 976; dosing (A), 975; interactions (A), 975; obesity treatment (A), 968; pharmacokinetics (A), 970; pharmacology (A), 969 otalol, compared with ibutilide (A), 40

Staphylacoccus oureus, pediatric deaths from methicillin-resistant ains (NC), 1136

nine-associated fatality (CR), 787; valitatus epilepticus, proate therapy (CR), 579

Stavudine, compared with nelfinavir mesylate (A), 328 Stevens—Johnson syndrome, amoxicillin/clavulinic acid (CR), 560:

sulfadiazine (L), 379 ison for treatment of pleural effu

sions and empyemas (A), 495 Stringer, Kathleen A, ACCP Research Institute Trustee (NC), 891 Study of Cardiovascular Risk Intervention by Pharmacists. (RR) 910

Sucralliate, enemas in radiation-induced proctitis (CR), 1274
Sulfadiazine, Stevens-Johnson syndrome induction in AIDS (L),

methoxarole, see Trimethoprim/sulfamethoxarole Sulfonviorens, compliance in a health maintenance organiz (RR), 281

nent of medication-induced headache (A), 68 Syncopy, cisapride-induced episodes (L), 251

Tacrime, Alzheimer disease treatment (A), 182, 443 www. dilatiazem interactions (CR), 680; itraconazole interacTalcapone, vitiligo association (L), 1228

ifen, brain tumor therapy (A), 82 Tardive Dyskinesia, etiology (A), 1195; vitamin E treatment (A),

Tazobactam, see Piperacillin/tazobactam
Theophylline, St. John's wort interactions (A), 502

Therapeutic controversies, aminoglycosides once-daily for gram-positive endocarditis (A), 600; glutamine supplementation in catabolic patients (A), 348; valproate therapy and polycystic ary syndrome (A), 1211

Thimerosal, content in vaccines (NC), 1021; hepatitis B vaccine vithout thimerosal (NC), 1242

Thrombocytopenia, amlodipine induction (L), 1126

Thrombocytonis, anagrelide treat

Ticlopidine, hepatotoxicity (CR), 939

Tirofiban, management of acute coronary syndromes (A), 718
Tolterodine, adverse effects (A), 1078; chemistry (A), 1074; clinical trials (A), 1076; comparison with oxybutynin (A), 1077; inter-actions (A), 1079; overactive bladder treatment (A), 1073; pharmacokinetics and pharmacodynamics (A) 1075; pharmacol (A), 1074; warfarin interactions (CR), 1173

Topotecan, brain tumor therapy (A), 826

Torsade de pointes, cisapride-clarithromycin interaction (CR), 22: haloperidol induction (CR), 1046

Toxicity, amphotericin B (CR), 680; bromfenac (CR), 945; ca mazepines (CR), 571; deferoxamine (L), 505; digoxin (CR), 796; fluconazole-induced carbamazepine toxicity (CR), 790; methadone, contamination of antibiotics (CR), 314: oxaprozin (CR), 942; polymyxins (A), 963; sertraline/venlafaxine (L), 381; ticlopidine (CR), 939; vinblastine (CR), 423

Transient ischemic attack, bupropion mimicking (CR), 305 Transplantation, liver, osteoporosis treatment (A), 233
Trazodone, interaction, carbamazepine (L), 1370

Tricyclic antidepressants, diabetic nephropathy use (A), 996; pharmacoeconomic analysis (A), 366

Trimethoprim/sulfamethoxazole, failure in Price pneumonia treatment (CR), 413; hepatic lesion imaging in AIDS (L), 1007

azone, cardiovascular effects (A), 229

Trovafloxacin, adverse reactions (A), 55; compared with cefpodoxime (A), 55, ceftriaxone (A), 55, ciprofloxacin (A), 55, clindamycin (A), 55, erythromycin (A), 55, metronidazole (A), 55; cost (A), 56; exfoliative dermatitis (VO), 1122; interactions, review (A), 56; pharmacology (A), 49; pharm Tuberculosis, rifapentine treatment (A), 1203 acokinetics (A), 49

Tuberculous meningitis, treatment of multidrug-resistant disease (CR), 1184

U-Z

Urinary incontinence, tolterodine tre atment (A) 1073

Urokinase, streptokinase comparison for treatment of pleural effusions and empyemas (A), 495

Vaccination, hepatitis A (A), 612; hepatitis B vaccine with

thimerosal (NC), 1242; impact in the decade (NC), 663; Lyme disease, availability of vaccine (NC), 395; Lyme disease, preven tion (A), 723; national coverage levels (NC), 1242; rotavirus, insception among vaccine recipients (NC), 1020; rotavin tetravalent vaccine (A), 833; thimerosal in vaccines (NC), 1021; varicella-zoster (A), 61

Valarnate, edema (L), 1370

Valproic acid, alopecia association (A), 634; headache, mar ment of medication-induced (A), 69; HIV patient use (A), 1113; polycystic ovary syndrome association (A), 1211; status epilepticus therapy (CR), 579

Vancomycin, anaphylaxis induction (CR), 1043; concentrations in

end-stage renal disease (L), 116, (A), 1329 Varicella-zoster, antiinfectives update (A), 610; vaccination (A), 611 Vasopressors, oral drug management of autonomic dysfunction

Venlafaxine, bupropion combination therapy for tredepression (CR), 701; diaphoresis and pruritus with extended-re-

lease venlafaxine (L), 1009; liver damage with sertraline (L), 381; Vigabatrin, adverse reactions (A), 1281; compared with carbamazepine (A), 1279; cost (A) cost; pediatrics (A), 1280; pharma tics (A), 1278; pharmacology (A), 1278; visual dysfunction (O), 1367

Vincristine, brain tumor therapy (A), 824 Visual observations, clofazimine crystals, 250; crythema multi forme from phenytoin, 748; trovafloxacin-associated exfoliative

Vitamin B₁₂, deficiency with omeprazole (A), 641 Vitamin E, tardive dyskinesia treatment (A), 1195

Vitiligo, talcapone and levodopa association (L), 1228 Vlasses, Peter H, executive director, American Council on Pharm

ceutical Education (NC), 664

Warfarin, clarithromycin interaction ns (CR), 796; diarrhea a tion with INR elevation (CR), 301; green tea inhibition (CR), 426; interacti on with ocular chloramphenicol (L), 114; tolte interactions (CR), 1173

Wegener's gran nous immune globulin tr ment (CR), 1055

Wertheimer, Albert I, president, Administration Pho of International Pharmaceutical Federation (NC), 763 Zidovudine.compared with nelfinavir mesylate (A), 329

Ziprasidone, adverse effects, drug interactions, and costs (A), 210; pharmacology, pharmacokinetics, and efficacy (A), 73

AUTHOR INDEX

A-B

Abou-Saif, Alaa (coauthor) see Wyderski, Richard J. 787 Ackman, Margaret L (author) Use of Nonprescription Medicati by Patients with Congestive Heart Failure (RR), 674; (coauthor ee McAlister, Finlay A. 289; (coauthor) see Tsuvuki, Ross T.

Acufia-Reina Lourdes (countbor) we Mateuide Antonio, Invier-

Agrawal, Radheshyam M (countror) see Limsure. David L. 560 Akinbi, Medinat S (author) Benzodiazepines in the Home Treatent of Acute Seizures (A), 99

Al-Tawfiq, Jaffar A (author) Therapeutic Failure of Trimethoprim/Sulfamethoxazole in the Treatment of Pneumocystis carinii Pneumonia (CR), 413

Alao, Adekola O (author) High-Dose Olanzapine Therapy i Schizophrenia (L), 1228; (coauthor) see Yolles, Jennifer C, 931 ano, Shirley A (coauthor) see Zaim, Sina, 312

Alderman, Christopher P (author) Possible Interaction Between Nefazodone and Pravastatin (L.), 871

Alghasham, Abdullah A (author) Trovafloxacin: A New Fluoro-

uinolone (A), 48

Aljazníri, Abdulrazaq (coau nor) see Smith, Joseph K. 301 Altun, Bülent (coauthor) see Usalan, Celalettin, 1126 Amir, Jacob (coauthor) see Basel-Vanagaite, Lina, 1370 Amitai, Yona (author) Automatic Autoinjectors Hazard: Penetration Through Bone (L), 751

Amsden, Guy W (coauthor) see Garey, Kevin W. 218 Arici, Mustafa (coauthor) see Usalam, Celalettin, 1126 Armenta, Wendy A (coauthor) see Alno, Adekola O. 1228; (coau-

thor) see Yolles, Jennifer C, 931 Autret-Leca, Elisabeth (coauthor) see Bourgade, Bruno, 1009 Avent, Minyon L (author) Comparing the Delivery of Albuterol Metered-Dose Inhaler via an Adapter and Spacer Device in an In Vitro Infant Ventilator Lung Model (RR), 141; (author) Evalua ing the Delivery of Nebulized and Metered-Dose Inhalers in an In Vitro Infant Ventilator Lung Model (RR), 144

Badr, M Gamal Abdul Ghany (coauthor) see Zolezzi, Monica, 380 Bagheri, Haleh (author) Potentiation of the Acenocoumarol Antico-

agulant Effect by Acetaminophen (L), 506
Bailey, Benoit (coauthor) see Einarson, Adrienne, 112 Bailey, Karen L (coauthor) see Venturini, Francesca. 281 Bailey, Lamar E (coauthor) see Chapman, Derek C. 775 Bajjoka, Iman E (coauthor) see Ng, Tien MH, 233 Baker, Ronda K (coauthor) see Nebel, Anita, 502 Raker, Sharon Young (author) book review, 1012

Balmes, Pierre (coauthor) see Champagne, Stéphane, Balog, Denise L (coauthor) see Maltz, Helene C, 1176 Bardeta, Jeffrey F (author) see reproductive and Urokinase for the Treatment of Pleural Effusions and Empyemas (A), 495 Barmes, Julie F (coauthor) see Tanna, Saloni B, 1180 Barone, Joseph A (author) Domperidone: A Peripherally Acting

Dopamine, Receptor Antagonist (A), 429

Basel-Vanagaite, Linn (author) Edema Associated with Valproate

Therapy (L), 1370

ncenzo (coauthor) see Capone, Domenico, 1124 Bayliff, Charles D (coauthor) see Maharaj, Siobhan, 1188 Beauchesne, Marie-France (Author) Etidronate and Alendr in the Treatment of Postmenopausal Osteoporosis (A), 587

Beeri, Ronen (coauthor) see Amitai, Yons, 751 Bell, Edward A (author) Pyloric Channel Stricture S High-Dose Ibuprofen Therapy in a Patient with Cystic Fibr

Ben-Vehuda, Dina (coauthor) see Lossos, Izidore S. 253 Benjamin, Suzanne (author) Erythema Multiforme Secondary to Amoxicillin/Clavulanic Acid Exposure (VO), 109

Bernal, Carlos (author) Hydrochlorothiazide-Induced Pulm Edema and Associated Immunologic Changes (CR), 172 Bernhard, N Bachaud (coauthor) see Bagheri, Haleh, 506 Berning, Shaun E (coauthor) see De Vincenzo, John P, 1184

Berryman, David M (author) book review, 1128 Bieszk, Nella (author) The Efficacy of Extended-li Omeprazole in Keeping Gastroesophageal Reflux Disease Patients Symptom Free (A), 638

Biggs, Rosemarie S (coauthor) see Tsuyuki, Rous T, 910
Bikin, Dule (author) An ABBOTTBASE Calculation Error (L.), 1230 Billuns, Sarah J (coauthor) see Isaksen, Sune Faurschon, 406 Bizjak, Eric D (author) Procainamide-Induced Psychosis: A Case Report and Review of the Literature (CR), 948

Blake, Kathryn V (author) Montelukast: Data from Clinical Trials in the Management of Asthma (A), 1299

Blank, Douglas U (coauthor) see Haskin, Janet A, 800 Biana, Dougnas C (coauthor) see Hasian, Jamee A, 500 Blayae, Jean-Pierre (coauthor) see Champagne, Stépha Blough, David K (coauthor) see Gray, Shelly L, 1147 Boh, Larry E (coauthor) see Hayney, Mary S, 723

Bolli, Peter (coauthor) see Gooderham, Melinda J. 796; (coauthor) see Gooderham, Melinda J. 1375 Boomershine, Jason E (coauthor) see Boomershine, Kellie H. 1195 Boomershine, Kellie H (author) Vitamin E in the Treatment of Tardive Dyskinesia (A), 1195

Bosch, Anna (coauthor) see Sahaté, Mônica. 1228
Bosker, Robbert JI (coauthor) see Brouwers, Paul JAM. 113 Bourgade, Bruno (author) Raynaud's Syndrome in a Patient Treatwith Milnacipran (L), 1009 Boyce, Eric G (coauthor) see Umland, Elena M, 1315

Boyd, Eddie L. (conuthor) see Smith. Scott P. 294. Bradford, Gregory S (author) Omeprazole and Vitamin B12 Deficiency (A), 641

m. John (cr thor) see Uderman, Howard D. 525 Briceland, Laurie L (coauthor) see Kim, Jooran S. 116: 6 thor) see Tam. Vincent H, 600; (coauthor) see Triller, Darren

Briggs, Andrea (author) Impact of Osteoarthritis and Anal nt on Quality of Life of an Elderly Popu Bristow, Michael R (coauthor) see Lindenfeld, JoAnn, 1266 Brodmerkel, George J Jr (coauthor) see Limauro, David L, 560 Brody, Eric A (coauthor) see Bizjak, Eric D, 948

neselver, Amy E. (author) An Interdisciplinary Mock Trial Involving Pharmacy, Law, and Ethics (A), 850; (author) eithics in Christianity and Health Care: Can "Character" Be Defined in This Interdisciplinary Course (A), 489

Brooks, Joseph C (author) Noncardiogenic Pulmonary Edema Im liately Following Rapid Protamine Administration (CR), 927 Brooks, Valerie G (coauthor) see Shelton, Penny S. 808 Brooks, Wesley G (author) Role of Anagrelide in the Treat sis (A), 1116

wers, Paul JAM (author) Photo with Interferon Alfa-2a (L), 113

Brown, Candace S (author) Atypical Antipsychotics Part II: Adverse Effects, Drug Interactions, and Costs (A), 210; (coauthor) see Markowitz, John S. 73

rown, Yvonne L (coauthor) see Avent, Minyon L, 141,144 Bryce, Elizabeth A (coauthor) see Marra, Fawziah O, 156 Buchanan, James (author) Comment: Cidofovir in the Treat of Cytomegoviral Disease (L), 752

Buck, Marcia L (coauthor) see Elliott, Ellie SR, 419 Budris, William A (author) High Anion Gap Metabolic Acidosis Associated with Aminocaproic Acid (CR), 308 Bui, LanChi L (author) Possible Interaction Between Cyclosporine

and Chloramphenicol (L), 252 Buisán, María-José (coauthor) see Mateu-de Antonio, Javier, 873

Buring, Shauna M (coauthor) see Taylor, Charles T, 1055 Burgess, David S (author) A Time-Kill Evaluation of Clarithr cin and Azithromycin Against Two Extracellular Pathogens and the Development of Resistance (RR), 1262

Burke, John P (author) Authors' Reply: Evaluation of the Clinical and Financial Impact of Intravenous Erythromycin Therapy in Hospitalized Patients (L.), 1372; (coauthor) see Classen, David C, 669; (coauthor) see Evans, R Scott, 1026

Burke, Mark S (coauthor) see Johnson, James R, 1043 Butts, John D (coauthor) see Rublein, John C, 899 Buzak, Kimberly A (coauthor) see Ackman, Margaret L, 674

C-E

Cady, Paul S (coauthor) see Culbertson, Vaughn L. 541 Camacho, Maria T (coauthor) see Glover, Mark L, 416 Campbell, Jeffrey B (coauthor) see Ackman, Margaret L, 674 Campomori, Annalisa (coauthor) see Nonino, Francesco, 644 Capone, Domenico (author) Effects of Itraconazole on Tacr

Blood Concentrations in a Renal Transplant Recipient (L), 1124 Carette, Bernard D (coauthor) see Olivier, Pascale B, 382 Carlisle, Steven S (author) Chlamvdia pneumoniae and Coronary Heart Disease (A), 615

Carrión-Carrión, Carmen (author) Fatal Stevens-Joh drome in an AIDS Patient Treated with Sulfadiazine (L.), 379
Carroll, Richard C (coauthor) see Baker, Sharon Young. 1012

Carson, John J (coauthor) see Zeolla, Mario M, 939 Carter, Barry L (coauthor) see Ellis, Samuel L, 1269; (coa see Isaksen, Sune Faurschou, 406 Carter, Russell W (coauthor) see Limauro, David L. 560

Catalán, Carlos (coauthor) see Palop, Vicente, 382 Cave, Andrew (coauthor) see Tsuyuki, Ross T. 910

Cha, Yoon Ju (author) Angioedema Due to Losartan (CR), 936 Champagne, Stéphane (author) Chronic Constrictive Pericardit Induced by Long-Term Bromocriptine Therapy: Report of Two

Chan, Anthony TC (coauthor) see Chang, Sophie, 646 Chan, Lesley SY (coauthor) see Chang, Sophie, 646 Chan, Thomas YK (author) Pyridoxine Ineffective in Is duced Psychosis (L.), 1123 Chain-Tompkins, Noreen H (coauthor) see Limmuro, David L, 560

Chang, Sandra W (author) Absorption of Rectally Administ Phenytoin: A Pilot Study (RR), 781

Chang, Shu-Ying (coauthor) see Uderman, Howard D, 525 Chang, Sophie (author) Utilization and Monitoring of Amino sides in Oncology Patients at a Hong Kong Government Hospital

Chang, Wei-Ching (coauthor) see Tsuvuki, Rom T. 910 Chapman, Derek C (author) Accuracy, Clinical Correlati Patient Accentance of Two Handheld Prothrombin Time Monioring Devices in the Ambulatory Setting (RR), 775 Chappell, Kimberly A (author) Is Valproate Phan

sociated with Polycystic Ovaries? (A), 1211 Cheigh, Jhoong S (coauthor) see Maltz, Helene C, 1176 Chicella, Mike F (coauthor) see Hovinga, Collin A, 579 Chittivelu, Subramanyam (author) Comment: Hydrochloro zide-Induced Pulmonary Edema and Associated Immunologic

Chow, Albert W (coauthor) see Smith, Steve J. 27 Classen, David C (author) Clinical and Financial Impact of Intra-venous Erythromycin Therapy in Hospitalized Patients (RR). hor) see Burke, John P, 1372; (coauthor) see Evans, R Scott, 1026

Cleary, John D (coauthor) see McNicholi, Ian R, 607; (c see Sullivan, Sabra, 1369

Carly, Marisage (coauthor) see Venturini, Francesca, 281 Coley, Rebecca MR (author) book review, 119 Collins, Michael (author) Potential Underreporting of Intravenous

Phenytoin Adverse Events (L), 111 Colucci, Vincent J (author) Tolterodine-Warfarin Interaction (CR),

Conner, Therese M (author) A Critical Review of Selected Phan macoeconomic Analyses of Antidepressant Therapy (A), 364 Conry, Colleen M (countror) see Ellis, Samuel L, 1269 Corey, PJ (author) Amphetamines to Counteract Op Sedation (A), 1362

Corriess, Christopher L (coauthor) see Rabkin, John M, 945 Corrocher, Roberto (coauthor) see Lombardi, Sara M, 571 Costs, Estelle (coauthor) see Champagne, Stéphane, 1050 Coyle, James D (author) book review, 1377 Criner, Tonyn M (author) Dextromethorphan and Diabetic Neu-

ronathy (A), 1221 or) see Conner, Therese M. 364; (cor

thor) see Lee, Jerry W. 554 ulbertson, Vaughn L (author) Positive Impact of a Follow-Up Phone Call to Community Pharmacies in a Medicaid Drug Uti-

lization Program (RR), 541 Cushing, Herbert E (coauthor) see Al-Tawfiq, Juffar A, 413 Cuatong, Herbert E (coauthor) see Al-Tawfin, Juffar A. Cudler, Neaf B. (coauthor) see Krall, Wanda J. 441 da Silva, Jack H (coauthor) see Chang, Sandru W. 781 Daston, James T (coauthor) see Hovinga, Collin A. 579 Daschner, Franz D (coauthor) see Districh, Eva S. 1125 Davis, Larry J (coauthor) see Buchanan, Jumes, 752 Davy, Jean-Marc (coauthor) see Champagne, Stéphane, 1050 De Vincenzo, John P (asthor) Multidrug-Resistant Tuberculous Meningitis: Clinical Problems and Concentrations of Second-Line Antituberculous Medications (CR), 1184

Degen, Lucas PM (coauthor) see Loliman, Joseph JHM, 645 rey, Carol L (coauthor) see Uderman, Howard D, 525 Delgado, Rafael Garcín (coauthor) see Romero, Alberto

Desoky, Ehab Said El (Author) Once-Versus Twice-Duily Administration of Amikacin in Pediatric Patients with Bronchonneumo inia: Plasma Drug Concentration and Bayesian Pharmacokinetics Estimation (L.), 749

DeVane, C Lindsuy (author) No Mourning for the Convention
Antipsychotics: The Dawn of the Atypical Agents (O), 107 Dickensheets, David L (coauthor) see Lewis, James R, 792 Dietrich, Eva S (author) Cost-Effectiveness of Macrolides in Lower

Respiratory Tract Infections (L), 1125 Dixon, Domeeka A (author) Indirect Modulation of Dopar Receptors as Potential Pharmacotherapy for Schizophrenia: I. Adenosine Agonists (A), 480

Dominguez, Karen D (author) Treatment of RSV Pneumonia in

Adults—Evidence of Ribavirin Effectiveness? (A), 739 Domínguez-Gil, Alfonso (coauthor) see Otero, María-Joné, 251 Dorko, Craig S (coauthor) see Chapman, Derek C, 775 Dorson, Peter G (coauthor) see Lee, Jerry W, 554 Driscoll-Bannister, Susan M (coauthor) see Rafi, John A, 769 Dulli, Douglas A (author) Naratriptan: An Alternat (A), 704

Dunton, Charles J (coauthor) see Flory, Stefanie M, 584 Duplagia, Beth A (author) Treatment of Childhood Hypen terolemia with HMG-CoA Reductase Inhibitors (A), 1224 Duvel, James M (coauthor) see Budris, William A. Dzavik, Vladimir (coauthor) see Tsuvuki, Ross T. 910 Eades, Shannan K (coauthor) see Hovinga, Collin A. 579 Echevarria, Kelly L (author) Hyperlipidemia Associated with Pro-

tease Inhibitor Therapy (A), 859 Edwards, Robin (coauthor) see Shepherd, Greene, 812 Einarson, Adrienne (author) Pregnancy Outcome of Women Ex-

ed to Pinavenum Due to a Dispen sing Error (L), 112 ics in a Neonate Receiving Extracorporeal Membrane Oxygenation (CR), 419 Elliott, Ellie SR (author) Phenobarbital Dosing and Pharmacokinet

Ellis, Samuel L. (author) Bell's Palsy in an Older Patient with Un-controlled Hypertension Due to Medication Nonadherence (CR), Emamian, Effat-S (coauthor) see Fatemi, S Hossein, 701

Enlow, Ann M (coauthor) see Ynnareudeewong, Weeramij, 7 Erdem, Yunus (coauthor) see Usulan, Celalettin, 1126 Ernst, Michael E (author) Methylxanthine Use in Anaphylaxis: What Does the Evidence Tell Us? (A), 1001 Eron, Joseph J (coauthor) see Rublein, John C, 899 Erush, Sazah C (coauthor) see Klatky, Denise E. 11 Evans, Martin E (author) Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria

Evans, R Scott (author) Evaluation of a Computer-Assisted Antibiotic-Dose Monitor (RR), 1026

F-G

Fan-Havard, Patty (author) Author's Reply: Cidofovir in the nent of Cytomegoviral Disease (L) Farris, Karen B (coauthor) see Pickard, A Simon, 1167; (conu thor) see Tsuyuki, Ross T, 910 Farver, Debra K (author) Quinine-Induced Hepatotoxicity (CR), 32 nterni, S Hossein (author) Venlafaxine and Bupropion Combinati Therapy in a Case of Treatment-Resistant Depression (CR), 701 Fedyk, Renee (coauthor) see Song, Karen H. 375 Fenix, Lori A (coauthor) see Dixon, Domeeka A. 480

Figueras, Albert (coauthor) see Subuté, Mônica. 1228 Fletcher, Courtney V (author) Pharmacologic Considera eutic Success with Antiretroviral Agents (A), 989

Flory, Stefanie M (author) Onycholysis Associated with Weekly Administration of Paclitaxel (CR), 584

Flynn, Barbara L (author) Author's Reply: Risk of Drug-Dis and Disease-Drug Interactions with Anticonvulsants in HIV Positive Patients (L.), 1375; (author) Pharmacologic Management of Alzheimer Disease Part I: Hormonal and Emerging Investiga-tional Drug Therapies (A), 178; (author) Pharmacologic Management of Alzheimer Disease Part II: Antioxidants, Antihypertensives, and Ergoloid Derivatives (A), 188; (author) Pharmacologic

stves, and Ergotoid Derivatives (A), 188; (author) Pharmacologic Management of Alzheimer Disease Part III: Nonsteroidal Antiin-flammatory Drugs—Emerging Protective Evidence? (A), 840 Foisy, Michelle M (coauthor) ser Tseng, Alice Lin-lin, 461; (coau-thor) see Tseng, Alice Lin-lin, 1373 Foote, Jan M (coauthor) see Bell, Edward A, 693

Force, Rex W (coauthor) see Culbertson, Vaughn L. 541
Force, Wendy S (coauthor) see Culbertson, Vaughn L. 541 Fort, John A (author) Pseudotumor Cerebri Secondary to Inter diate-Dose Cytarabine HCl (CR), 576

Foster, Shonda A (author) Home Blood Glucose Monitoring (A),

Frank, Uwe author) see Dietrich, Eva S, 1125

Frazier, Lisa M (coauthor) see Rafi, John A, 769
Freitag, Vanessa L (Author) Effect of Short-Term Rifampin on Stable Cyclosporine Concentrations (L), 871

Frey, Otto R (author) Adverse Effects in a Newborn Infant Bri
Fed by a Mother Treated with Doxepin (CR), 690

Frighetto, Luciana O (coauthor) see Marra, Fawziah O, 156 Fromm, Laurie A (author) Oxacillin-Induced Tissue Necrosis (CR) 1060 Fuller, Stephen H (coauthor) see Smith, Joseph K, 301

Gajewski, Lidia K (author) Characterization of Rash with Indinavir in a National Patient Cohort (RR), 17

Gal, Peter (coauthor) see Avent, Minyon L. 141; (coauthor) see

Avent, Minyon L, 144
Gales, Mark A (author) Is Rectally Administered Cisapride an Effective Prokinetic Agent? (A), 1217; (coauthor) see Knight, Marcenia R, 872

Galloway, James M (coauthor) see Bizjak, Eric D, 948 Galvin, Donna (coauthor) see Tsuyuki, Ross T, 910 Garcin, Esther Durán (author) Treatment of Malignant Mela

Garey, Kevin W (author) Intravenous Azithromycin (A), 218 Garnett, William R (coauthor) see Collins, Michael, 111; (coau

thor) see Rafi, John A, 769
Garrelts, James C (author) The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an IV Bolus or as a Rapid Infusion (RR), 1258

Gautam, Monica (author) Alopecia Due to Psychotropic Medica-

Gentile, Antonio (coauthor) see Capone, Domenico, 1124 Germain, Marie-Laure V (coauthor) see Olivier, Pascale B, 382 Ghiotto, Elisabetta (coauthor) see Leone, Roberto, 114 Gholami, Kheirollah (author) Factors Associated with Previ ity, Predictability, and Severity of Adverse Drug Reactions (IR),

Gibson, Gene A (coauthor) see Kinky, Denise E, 11 Gidal, Borry E (author) Vigabatrin: A Novel Therapy for Seizure

Disorders (A), 1277; (coauthor) see Collins, Michael, 111
Gill, John (author) Hepatotoxicity Possibly Caused by Amphotericin B (CR), 683 Gilman, Jamie T (courthor) see Gidal, Barry E, 127

Gloredi, Domenico G (countro) see Lombardi, Sara M. 571 Glover, Mark L (author) see Lombardi, Sara M. 571 Glover, Mark L (author) The Use of Alteplase in a Newborn ceiving Extracorporcal Membrane Oxygenation (CR), 416 Goad, Jeffrey A (author) Reverbilds (Nonthombocytopenic Pile Purpura Associated with Metoclopramide (CR), 35 Geldonial Barro, B (pottor)

Goldspiel, Barry R (author) Paclitaxel Compatibility with Ethylene

Vinyl Acetate Bags (L), 873 Gonzales-Blanco, Mercedes (co

Goode, Jenn-Venable "Kelly" R (coauthor) see Brooks, Wesley

G, 1116; (coauthor) see Foster, Shonda A, 355 Gooderkam, Melinda J (author) Authors' Reply: Clarith Direction (L.), 1375: (author) Concomitant Direction Toxicity and Warfarin Interaction in a Patient Receiving Clarcin (CR), 796

Gordon, Fredricka S (coasthor) see Triller, Durren M. 1122 Gow, Robert M (coauthor) see Seto, Winnie, 9 Graher, Mark A (coauthor) see Ernst, Michael E, 1001 Graham, Diane L (coauthor) see France, Laurie A, 1060 Grande, Thomas P (coauthor) see Hammond, Constance M, 1160 Gray, Shelly L (author) Adverse Drug Events in Elderly Patients Receiving Home Health Services Following Hospital Discharge

Grimone, Andrew J (coasthor) see Gajewski, Lidin K. 17 Grinnley, Surn R (coauthor) see Penzak, Scott R, 1372 Grothe, Raynu (coauthor) see Bell, Edward A, 693 Grothe, Rayna (coauthor) see Bell, Edward A, 693 Grunnke, Mike M (coauthor) see Hayney, Mary S, 723 Gony, David RP (author) Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent (A), 1083

Gums, John G (coasthor) see Lewis, James R. 792 Gupchup, Gireesh V (coasthor) see Singhal, Pameet K. 1336 Gutiérrez, Maria Angeles (coasthor) see Ortin, Miguel, 175

H-J

thor) see Flory, Stefanie M. 584 Hagmeyer, Kathleen O (author) Role of Lamivudine in the Treatment of Chronic Hepatitis B Virus Infection (A), 1104; (coaument of Chronic Hepatitis B Vir thor) see Kamm, Gayle L, 451

Halverson, Valerie J (coauthor) see Yamreudeewong, Weeranuj.

Harmann, Gale L (conuthor) see Chapman, Derek C, 775
Hammond, Constance M (author) Economic Evaluation of
Rispendone in an Outpatient Propulation (RR), 1160
Hansen, Charles J (coauthor) see Avent, Minyon L, 141; (conuthor) see Avent, Minyon L, 144

Hansen, Lea Ann (author) book review, 877 Hanson-Divers, Christine (coathor) see Pradel, Françoise G, 400 Harbeck, Ronald J (author) Clofazimine Crystals in the Cytoplasm

of Pulmonary Macrophages (VO), 250

Hardin, Thomas C (coauthor) see Echevarria, Kelly L. 859 Harger, Beau (coauthor) see Sullivan, Sabra, 1369 Harrison, Bruce R (coauthor) see Moss, Patrick E. 423 Hartzema, Abraham G (coauthor) see Pradel, Françoise G, 400 Haskin, Janet A (author) Acute Renal Failure After Large Doses of

Intravenous Immune Globulin (CR), 800 lastings, Rhonda S (coauthor) see Burgess, David S, 1262 Hauben, Manfred (author) Comment: Papular Rash and Bilateral pine (L), 1374 Pleural Effusion Associated with Clozapine (L.), 1374 Haverstick, Doris M (coauthor) see Williamson, John C, 906

Hayney, Mary S (author) Lyrne Disease Prevention and Vaccine Prophylaxis (A), 723; (coauthor) see Martin, Julie K, 474 Haznedaroğlu, Seminur (coauthor) see Karauslan, Yasar. 1229 Hebert, Mary F (author) Diltiazem Inc. ns (CR), 680

Heck, Amy M (coauthor) see Corey, PJ, 1362 Herner, Sheryl J (author) Epoprostenol in Primary Pulm pertension (A), 340

Heyneman, Catherine A (coauthor) see Wall, Geoffrey C, 499 Hickman, Scot (coauthor) see Moss, Patrick E, 423 Hillaire-Buys, Dominique (coauthor) see Champagne, Stéphane

Ho, Paul C (coauthor) see Kueh, Yan Koon, 503 Hogan, Kevin P (coauthor) see Karagianis, James L, 623 Holimon, Teresa D (coauthor) see Ward, Michael W, 1356 Hollik, Deborah A (coauthor) see Mylonakis, Eleftherins, 557 Holtzer, Christopher D (author) The Use of Combination Antiretroviral Therapy in HIV-Infected Patients (A), 198 Hoover, Rhonda (coauthor) see Song, Karen H, 375 Horan, Jennifer L (coauthor) see Burgess, David S, 126. Hori, Shigeaki (coauthor) see Morikawa, Norifumi. 115; (co thor) see Morikawa, Norifumi, 952.

Hovinga, Collin A (author) Use of Intravenous Valproate in Three Pediatric Patients with Nonconvulsive or Convulsive Status Enilepticus (CR), 579

loward, Patricin A (author) Ibutilide: An Antiarrhythmic for the Treatment of Atrial Fibrillation or Flutter (A), 38 Huang, Dorcas D (coauthor) see Bui, Lanchi L, 252 Huang, Willam (coauthor) see Jiang, Tianrong Tim, 750 Humma, Larisa M (author) Bupropion Mimics a Transient Is-

chemic Attack (CR), 305 Husson, Robert N (coauthor) see De Vincenzo, John P. 1184 Hwang, Wayne (coauthor) see Kim, Kye Y. 381 Ikeda, Hiroaki (author) Acral Erythema Associated with High-

Dose Methotrexate Infusion (L.), 646

Imperatore, Paula (coauthor) see Capone, Domenico, 1124
Isaksen, Sure Faurschou (author) Estimating Risk Factors for Patients wit.) Potential Drug-Related Problems Using Electroni Pharmacy Data (RR), 406 Ito, Matthew K (coauthor) see Lin, Jennifer C. 16

Ito, Shinya (coauthor) see Juurlink, David N, 1375 Iwamoto, Aikichi (coauthor) see Taguchi, Hitomi, 503; (co see Takahashi, Takashi. 1007 Jackson, Cherry W (coauthor) see Chappell, Kimberly A. 1211

Jann, Michael W (coauthor) see Penzak, Scott R, 1372 Janzen, Laverne (author) An Overview of Levodopa in the Management of Restless Legs Syndrome in a Dialysis Population: Pharmacokinetics, Clinical Trials, and Complications of Therapy

Jennings, Heath R (author) Comment: Risk of Drug and Di ease-Drug Interactions with Anticonvalsants in HIV-Positive Pa-tients (L), 1373; (author) The Use of Valproic Acid in HIV-Posis (A), 1113

Jewesson, Peter J (coauthor) see Marra, Fawziah O, 156 Jiang, Tianrong Tim (author) Cyclosporine-Induced Encephalop thy Predisposed by Diltiazem in a Patient with Aplastic Anemia (1.), 750

uthor) see Palop, Vicente, 382 Jiménez-Torres, N Victor (coauthor) see Tortaiada-Ituren, Juan José, 804

Johnson, James R (author) Life-Threatening Reaction to Vancomvein Given for Noninfectious Fever (CR), 1043 Johnson, Jeffrey A (coauthor) see Pickard, A Simon, 1167; (coauthor) see Tsayuki, Ross T. 910

Jonassen, Jacob (coauthor) see Isaksen, Sune Faurs Jones, Gwynne (coauthor) see Koulouris, Zoë. 1191 Jones, Kelly W (author) book review, 255 Jones, Melissa M (coauthor) see Broeseker, Amy E, 850 Jonville-Béra, Annie-Pierre (coanthor) see Boargade, Bruno, 1009 Jordan, Namey S (author) book review, 255 Jons, Jacqueline D (author) Tricyclic Antidepressant Use in Diabet-

ic Neuropathy (A), 996 Juurlink, David N (autho thor) Comment: Clarithromycin-Digoxin InK-M

Kaback, Keith R (coauthor) see Tafreshi, Moham Kaftan, Osman (coauthor) see Karaaslan, Yasar. 1229 Kale-Pradham, Pramodini B (coauthor) see Bieszk, Nella, 638 Kamenofuchi, Yousuke (coauthor) see Morikawa, Norifumi, 952 Kamm, Gayle L (author) Allergic-Type Reactions to Cortico

Kaplan-Machlis, Barbara (author) Correction: Cyclooxygenase-Inhibitors (L), 376; (author) Health-Related Quality of Life in Primary Care Patients with Gastroesophageal Reflux Disea (RR), 1032; (author) The Cyclooxygenase-2 Inhibitors: Sa and Effectiveness (A), 979; (coauthor) see Wandstrat, Todd L., 833; (coauthor) see Lalkin, Arieh, 314

Kapur, Bhushan M (coauthor) see Lalkin, Arieh, 314 Karanslan, Yasar (author) Granulocytopenia Due to Nil Followed by a G-CSF-Induced Leukemoid Reaction (L.), 1229 Karagianis, James L (author) Clozapine-Associated Ne Malignant Syndrome: Two New Cases and a Review of the Liter-

Kaul, Alan F (coauthor) see Stoukides, Chervl A, 1287 Kawano, Hironori (coauthor) see Ikeda, Hiroaki, 646 Kawashima, Hisanori (coauthor) see Morikawa, Norifumi. 115:

(coauthor) see Morikawa, Norifumi, 952 Kendle, Julie B (coauthor) see Fan-Havard, Patty, 753 Kethu, Sripathi R (author) Oxaprozin-Induced Symptomatic Hepa totoxicity (CR), 942

Kihira, Kenii (cosuthor) see Ikeda, Hiroaki, 646 Kilpatrick, David M (coaut

Kim, Denise M (coauthor) see Dixon, Domeeka A, 480 Kim, Jooran S (author) Clinical Significance of Falsely Elevated ntrations in End-Stage Renal Disease (L), 116 Kim, Kve Y (author) Acute Liver Damage Possibly Related to Ser-

traline and Venlafaxine Ingestion (L.), 381 Kimber, Shane (coauthor) see McAlister, Finlay A, 289 Kimura, Akiro (coauthor) see Ikeda, Hiroaki, 646 Kinky, Denise E (author) Economic Impact of a Drug Information rice (RR), 11

Kirking, Dunne M (coauthor) see Smith, Scott R, 294 Kist, David A (coauthor) see Faterni, S Hossein. 701 Kitaura, Teruaki (coauthor) see Ikeda, Hiroaki. 646 Klein-Schwartz, Wendy (coauthor) see Shepherd, Greene. 812 Klostermeyer, Barbara Storyk (coauthor) see Kaplan-Machlis, Rarbara, 979: (coauthor) see Kapian-Machlis, Barbara, 1376 Knight, Marcenia R (author) ACE Inhibitor Switch in an Indig Community Clinic (L), 872

Kolesar, Jill M (author) book review, 119 Koren, Gideon (author) Correction: Pediatric Methadone Poison (L), 1011; (coauthor) see Einarson, Adrienne. 112; (coauthor) see Lalkin, Arieh, 314

Koulouris, Zoë (author) Metabolic Acidosis and Coma Follor Severe Acetaminophen Overdose (CR), 1191

Kovaes, Michael J (coauthor) see Maharaj, Siobkan, 1188 Kovalick, Lawrence J (coauthor) see Wittbrodt, Eric T, 565 Krall, Wanda J (author) Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease (A), 441

Krauss, Gregory L (author) Vigabatrin: An Effective Antiepilepsy -Balancing the Risks of Visual Dysfunction (O), 1367 Kroll, David J (coauthor) see Nehel, Anita: 502

Kueh, Yan Koon (author) Sublingual Administration of All-tr retinoic Acid to a Comatose Patient with Acute Promyelocytic Leukemia (L), 503

Kuhl, David R (coauthor) see Chang, Sandra W, 781 Lake, Kathleen D (coauthor) see Freitag, Vanessa L, 871 Lalkin, Arieh (author) Contamination of Antibiotics Resulting in Severe Pediatric Methadone Poisoning (CR), 314

Lam, Annie Y (coauthor) see Hebert, Mary F, 680 Lansford, Charles L (coauthor) see Kethu, Sripathi R, 942 Laskin, Mitchell S (coauthor) see Kinky, Denise E, 11 Lavin, Megan N (coauthor) see Farver, Debra K, 32 Le Garé, Claude (coauthor) see Bourgade, Bruno, 1009 Leho, Terri D (coauthor) see Harbeck, Ronald J. 250 LeDrew, Kellie K (coauthor) see Karagianis, James L, 623 Lee, Audrey J (coauthor) see Smith, Steve J. 27 Lee, Jerry W (author) Seizure Associated with Olanzapine (Leehey, Maureen A (coauthor) see Ellis, Samuel L, 1269 Leikin, Jerrold B (coasthor) see Sigg, Todd R. 1123 Leone, Roberto (author) Potential Interaction Between Warfarin

and Ocular Chloramphenicol (L.), 114 Lewis, James R (author) Levofloxacin-Induced Bilateral Achilles Tendonitis (CR), 792

Li, Ronald C (coauthor) see Chang, Sophie, 646 Liao, Wei-chi (coauthor) see Uderman, Howard D, 525 Liew, Pearle PL (coauthor) see Koch, Yan Koon, 503 Limauro, David L (author) Amoxicillin/Clavulinate-As Hepatic Failure with Progression to Stevens-Johnson Syndrome

Lin. Jennifer C (author) Chronic Creatine Kinase Elevation Not sociated with HMG-CoA Reductase Inhibitor Treats

Lindenfeld, JoAnn (author) Hypotension with Dobutar adrenergic Antagonist Selectivity at Low Doses of Carvedilol (CR), 1266

Llopis-González, Agustín (coauthor) see Carrión-Carrión, Caren, 379

Llopis-Salvia, Pilur (coauthor) see Tortajada-Ituren, Juan José. thor) see Burke, John P, 1372; (coauthor)

see Classen, David C. 669

teraction (L), 1375

Lasten Peter S (consthur) are Zed Peter I 61 Lohman, Joseph JHM (author) Antiretroviral Therapy Increases Serum Concentrations of Amiodarone (L), 645

Lomburdi, Sara M (author) Severe Multisystemic Hypersensitivity Reaction to Carbamazepine Including Dyserythropoietic Anemia

Lossos, Izidore S (author) Cutaneous and Subcu Following Dexrazoxane-CHOP Therapy (L), 253

Lowe, Beverly (coauthor) see Williams, Bradley R, 149 Lower, Dennis L (coauthor) see Yamreudeewong, Weeranui, 7 Lowes, Brian D (coauthor) see Lindenfeld, JoAnn, 1266 Luque, Carla A (author) Sibutramine: A Serotonin-Nores

Reuptake-Inhibitor for the Treatment of Obesity (A), 96 Luzier, Aileen B (coauthor) see Wooster, Melissa B, 318 Lynch, PL Mark (coauthor) see Williamson, John C, 906 MacKnight, Chris (coauthor) see Rojas-Fernandez, Carlos H,

Maddix, Daniel S (coauthor) see Smith, Steve J. 27 Maharaj, Siobhan (author) Successful Anticoagulation with Dal-teparin in a Patient with Mechanical Heart Valves (CR), 1188 Mahoney, Jame E (coauthor) see Gray, Shelly L, 1147

Mahowald, Maren L (coauthor) see Johnson, James R. 1043 Maidment, Ian D (author) Lamotrigine—An Effective Mood Stahilizer? (A) 864

Malone, Daniel C (coauthor) see Isaksen, Sune Faurschou, 406 Maltz, Helene C (author) Rhabdomyolysis Associated with Concomitant Use of Atorvastatin and Cyclosporine (CR), 1176; (coauthor) see Wong, Shuk-Ling, 103

Mania, Emile (coauthor) see Champagne, Stéphane, 1050 Marcus, Esther-Lee (author) Marked Elevation of Serum Creating Kinase Associated with Olanzapine Therapy (CR), 697 Margolies, Jane (coauthor) see Williams, Bradley R, 149

Marinella, Mark A (author) Erythema Multiforme Possibly Due to

Prienyton (VO), 200 Markowitz, John S (author) Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy (A), 73; (coauthor) see Brown, Candace S, 210; (coauthor) see Chappell, Kimberly A.

Marra, Carlo A (author) book review, 1128; (coauthor) see Marra. Fawziah O. 156

Marra, Fawziah O (author) Cost-Minimization Analysis of Piperacillin/Tazobactam Versus Imipenem/Cilastatin for the Treatment of Serious Infections: A Canadian Hospital Perspective (RR), 156 Marrone, Christopher M (author) Safety Issues with Herbal Prod-

Martin, Julie K (author) Angiotensin-Converting Enzyme Gene Polymorphism: Is There a Link to Nephropathy in Patients with Type 1 Diabetes? (A), 474

Martinez, Maribeth C (author) Famotidine in the Ma Schizophrenia (A), 742

Martinez-Mir, Inocencia (coauthor) see Palop, Vicente, 382 Mateu-de Antonio, Javier (author) Lack of Toxicity in a Cladri-bine Extravasation (L), 873

Mauro, Laurie S (coauthor) see Herner, Sheryl J. 340 Mawer, George E (coauthor) see Wong, Ian CK, 1037 McAlister, Finlay A (author) Contemporary Utiliz in Patients with Atrial Fibrillation (RR), 289

McCombs, Jeffrey S (coauthor) see Venturini, Francesca. 281; (coauthor) see Williams, Bradley R. 149

McCoy, Laura K (coauthor) see Newton, Herbert B. 816 McKinley, George F (author) Riluzole: A Potential Therapy for HIV Dementia? (L), 114

McNicholl, Ian R (author) Antiinfectives Update: Focus on Tre ment and Prevention of Viral and Associated Infections (A), 607 McVoy, Heather J (coauthor) see Stoukides, Cheryl A, 1287 Melbourne, Kathleen M (coauthor) see Gajewski, Lidin K. 17 Melby, Michael J (coauthor) see Tafreshi, Mohammad J, 1252 Melko, George P (author) Treatment of Radiation-Induced Procities

with Sucralfate Enemas (CR), 1274
Mercier, Renée-Claude (coauthor) see Dominguez, Karen D, 739 Millart, Hervé G (coauthor) see Olivier, Pascale B, 382 Miller, Michael T (coauthor) see Triller, Durren M, 1122 Miller, Nell R (coauthor) see Krauss, Gregory L, 1367 Miller, Penny F (coauthor) see Beauchesne, Marie-France, 587 Miller, Sarah J (author) book review, 1129

Mimouni, Mare (coauthor) see Basel-Vanagaite, Lisa, 1370 Montague, Terrence J (coauthor) see Ackman, Margaret L, 674 Montastruc, Jean L (coauthor) see Bagheri, Haleh, 506 Montopoli, George (coauthor) see Yamreudeewong, Weeranuj.

Moore, Then R (coauthor) see Brown, Candace S. 210; (coauthor) see Markowitz, John S. 73 Morales-Suárez-Varela, MM (coauthor) see Carrión-Carrión,

Morán, Dominica (coauthor) see Otero, María-José, 25 Morgenstern, Nora E (coauthor) see Runcin, J Mark, 1073 Morgenthien, Elizabeth A (coauthor) see Uderman, Howard D,

Mori, Terunki (coasthor) see Morikawa, Norifami, 115; (con

thor) see Morikawa, Norifumi, 952.

Morikawa, Norifumi (author) Dose-Related Increases in Cere-brospinal Fluid Concentrations of Methotrexate in a Postoperative Patient with Glioblastoma (CR), 952; (author) Pharmacolcinetics of Etoposide in Plasma and Cerebrospinal Fluid in the Space Left by Tumor Removal (L), 115 Morris, Harold H (counthor) see Nair, Dileep R. 790

Morse, Gene D (coauthor) see Smith, Patrick F, 1329 Mortimer, Clive B (coauthor) see Tseng, Alice L, 167 Moss, Patrick E (author) Ototoxicity Associated with Vinblastin

Mover, Anne (consthor) see Bikin, Dule, 1230 Much, David R (coauthor) see Uderman, Howard D, 525 Mueller, Bruce A (coauthor) see Benjamin, Suzanne, 109 Munetz, Mark R (coauthor) see Hammond, Constance M, 1160 Munger, Mark A (coauthor) see Young, Melissa D, 920 Muruzábal, María José (coauthor) see Ortín, Miguel, 175 Mutran, Elizabeth J (coauthor) see Pradel, Françoise G, 400 Mylonakis, Eleftherins (author) Larr as Anticonvulsant Hypersensitivity Syndrome (CR), 557

N-P

Nahata, Milap C (author) Pediatric Drug Formulations: Challe and Potential Solutions (E), 247;(coauthor) see Alghasham, Abdullah A, 48; (coauthor) see Carlisle, Steven S, 615; (coauthor) see Pal, Vinita B, 325; (coauthor) see Temple, Mary E, 868; (coauthor) see Temple, Mary E, 1203; (coauthor) see Wandstrat. Todd L. 833

Nair, Dileep R (author) Potential Fluconazole-Induced Carbamazenine Toxicity (CR), 790

mura, Tetsuya (c thor) see Taguchi, Hitomi, 503; (coau thor) see Takabashi, Takashi, 1007

Narendran, Rajesh (coauthor) see Kim, Kye Y, 381 Nebel, Anita (author) Potential Metabolic Interaction Between St. John's Wort and Theophylline (L), 502 Neef, Cees (coauthor) see Brouwers, Paul JAM, 113

Neufeld, Julia M (coauthor) see Flory, Stefanie M, 584 Newton, Herbert B (author) Clinical Presentation, Diagno

Pharmacotherapy of Patients with Primary Brain Tumors (A), 816 Ng, Tien MH (author) Treatment Options for Osteoporosis in Chronic Liver Disease Patients Requiring Liver Transplantation

Nichol, Michael B (author) A Critical Evaluation of the Methodology of the Literature on Medication Compliance (RR), 531; (coau thor) see Venturini, Francesca, 281; (coauthor) see Williams, Bradley R 149

ligond, Jacques (coauthor) see Champagne, Stéphane, 1050 Nolan, Paul E Jr (coauthor) see Bizjak, Eric D. 948 Nonino, Francesco (author) Neuroleptic Malignant Syndrome Associated with Metoclopramide (L), 644 ord, Teresa C (coauthor) see Tafreshi, Moh

O'Brien, Jill M (author) Haloperidol-Induced Torsade de Pointes

O'Hara, Kathryn A (crossther) see Rafi, John A. 769 Okada, Fumihiko (author) Legal Problems Concerning the Use of Fluoxetine in Japan (L.), 752

Okajima, Kiyoko (cosuthor) see Okada, Fumihiko, 752 Okano, Gary J (author) A Comparison of Antihypertensive Medication Utilization Before and After Gusdeline Changes Using the Department of Defense Prescription Database (RR), 548

Olalla, José Ignacio (coauthor) see Ortín, Miguel, 175 Olivier, Pascale B (author) Elevation of Serum Creatinine Follow ing Fosinopril Therapy (L), 382 Olyaei, Ali J (coauthor) see Rabkin, John M. 945

Ordovás-Baines, Juan Pablo (coauthor) see Tortajada-Ituren. an José, 804

Orloff, Susan L (coauthor) see Rabkin, John M, 945 Ortin, Miguel (author) Miconazole Oral Gel Enhances Acenocou-marol Anticoagulant Activity: A Report of Three Cases (CR), 175 Oterino, Jose Angel Martín (coauthor) see Rodríguez, Angel

Otero, María-José (author) Interaction between Phenytoin and Ciprofloxacin (L), 251

Özilkan, Esin (consther) see Karaaslan, Yanar, 1229 Pai, Vinita B (author) Nelfinavir Mesylate: A Protease Inhibitor (A), 325

Palmer, Shirley M (coauthor) see McNicholl, Ian R, 607 Palmiero, Giuseppe (coauthor) see Capone, Domenico, 1124 Palop, Vicente (author) Acute Dystonia Associated with Fluvo -Metoclopramide (L), 382

Pan, Yu-Yuan (coauthor) see Hagmeyer, Kathleen O. 1104 Parker, Nicole G (coauthor) see Brown, Candace S. 210 Parks, Susan M (coauthor) see Umland, Elena M, 1315 Patarca, Roberto (coauthor) see Bernal, Carlos, 172 Patel, Deepeesh (coauthor) see Jiang, Tinnrong Tim, 750 Pathak, Dev S (coauthor) see Hammond, Constance M. 1160 Pearson, Vincent E (coauthor) see Chn. Yoon Ju. 936 Pedrós, Consuelo (coauthor) see Sahaté, Mônica, 1228 Peloquin, Charles A (coauthor) see De Vincenzo, John P. 1184; or) see Harbeck, Ronald J. 250

Peña, Maria Flores (coauthor) see Romero, Alberto Sánchez,

Penzak, Scott R (author) Comment: Significant Interactions with New Antiretrovirals and Psychotropic Drugs (L), 1372 Peralta, Francisco Galo (coauthor) see Ortin, Miguel, 175 Perdan, Carla S (coauthor) see Crimer, Tonya M, 1221 Perkins, Ruth J (coauthor) see Kim, Jooran S, 116 Pestotnik, Stanley L (coauthor) see Burke, John P, 1372; (co author) see Classen, David C. 669; (coauthor) see Evans, R Scott. 1026

Peterson, Andrew M (author) book review, 877 Peyriére, Hèléne (coauthor) see Champagne, Stéphane, 1 Phelan, Thomas F (coauthor) see Melko, George P, 1274 Phelps, Stephanie J (coauthor) see Hovinga, Collin A. 579
Phillips, Leslie C (coauthor) see Karagianis, James L. 623
Pickard, A Sianon (author) The Impact of Pharmacist Interve

Pickaire, A Station (author) rise impact or rearrances mervermons on Health-Related Quality of Life (RR), 1167 Pierce, Dana Reld (constitut) see Thompson, Dennis F, 93 Pierson, Jerome F (constitut) see Hammond, Constance M, 1160 Piquette, Rosemary K (author) Tornade de Pointes Induced by Cisannide/Clarithron cin Interaction (CR) 22

Pons, Jonn-Carlos P (consthor) see Mateu-de Antonio, Javier, 873 Pons, Maxime (coauthor) see Champagne, Stéphane, 1050
Pradel, Françoise G (author) Physician Over-the-Counter Drug
Prescribing Patterns: An Analysis of the National Ambulatory Medical Care Survey (RR), 400

Preston, Sandra L (coauthor) see Tam, Vincent H, 600 Privitera, Michael D (coauthor) see Gidal, Barry E, 1277 Pugh, Carol B (coauthor) see Rafi, John A, 769

R-S

asch, Ralph H (coauthor) see Rublein, John C, 899 Rabkin, John M (author) Fatal Fulminant Hepatitis Associated with Bromfenac Use (CR), 945
Raffa, Robert B (coauthor) see Dixon, Domeeks A, 480

Rafi, John A (author) Effect of Over-the-Counter Cimetidine on Phenytoin Concentrations in Patients with Seizures (RR), 769 Raisch, Dennis W (coauthor) see Singhal, Puneet K, 1336 Ralph, Edward D (coauthor) see Gill, John, 683 Raman-Wilms, Lalitha (author) book review, 1377 Ranno, Anthony E (coauthor) see Flynn, Barbara L. 188 Ransom, J Laurence (coauthor) see Avent, Minyon L. 141; (coau-

thor) see Avent, Minyon L. 144 Rapp, Robert P (coauthor) see Evans, Martin E, Rascati, Karen L (coauthor) see Okano, Gary J. 548 Nascata, Rairen L. (coauthor) sec Okano, Gary J. 538 Raymond, Kenneth (coauthor) sec Clanga, Sophie. 646 Reichert, Louis JM (coauthor) sec Lohman, Joseph JHM, 645 Reinfeldt, Gretchen (coauthor) sec Collins, Michael, 111 Remund, Daniel D (coauthor) sec Okano, Gary J. 538 Requena, Teresa (coauthor) see García, Esther Durán, 730 Revicki, Dennis A (coauthor) see Kaplan-Machlis, Barbara, 1032 Rey, Jose A (coauthor) see Luque, Carla A, 968 Reynolds, Robert P (coauthor) see Marra, Fawziah O, 156 Rich, Jay A (coauthor) see Janzen, Laverne, 86 Ricketts, William A (coauthor) see Avent, Minyon L. 144 Rinaldi, Christine (coauthor) see Umland, Elena M, 1315 Rivers, José O (author) Losartan-Induced Angioedema (CR), 933 Rivey, Michael P (coauthor) see Colseci, Vincent J. 1173 Robinson, Gordon (coauthor) see Zed, Peter J. 61 Rockwood, Robert P (coauthor) see O'Brien, Jill M, 1046 Rodriguez, Angel Súcchez (author) Unusual Toxicity of Deferox

Rogers, David P (coauthor) see Williamson, John C, 906 Rojas-Fernandez, Carlos H (author) Comment: Management of Alzheimer Disease (L.), 1374

Roland, Michelle (coauthor) see Holtzer, Christopher D. 198 Romanelli, Angela M (coauthor) see Umland, Elena M, 229 Romanelli, Frank (coauthor) see Jennings, Heath R, 1113; (coauthor) see Jennings, Heath R, 1373 Romero, Alberto Sánchez (author) Interaction Between Trazodone

and Carbamazepine (L.), 1370

Rose, Doug F (coauthor) see Hovinga, Collin A, 579 Rounds, Sharon (coauthor) see Mylonakis, Eleftherios, 557

Roxe, David M (coauthor) see Budris, William A, 308
Rublein, John C (author) Discontinuation Rates for Protease Inhibitor Regimens Containing Ritonavir 600 mg ve 400 mg plus Saquinavir 400 mg (RR), 899

gari, Sireesha (coauthor) see Kethu, Sripathi K, 942 Rukkanr Rusein, J Mark (author) Tolterodine Use for Symptoms of Overac tive Bladder (A), 1073

Sabaté, Mônica (author) Vitiligo Associated with Tolcapon Levodopa in a Patient with Parkinson's Disease (L), 1228 Sacks, Gordon S (author) Glutamine Supplementation in Catabolic Patients (A), 348

Salit, Irving E (coauthor) see Tseng, Alice L. 167 Sander, Josemir WAS (coauthor) see Wong, Ian CK. 1037 Santolava, Rosario (coauthor) see García, Exther Durán, 730 Sauers, Nathan M (coauthor) see Melko, George P, 1274 Schaafsma, M Ron (coauthor) see Brouwers, Paul JAM, 113 Scheidt, Peter (coauthor) see Frey, Otto R, 690 Schneider, BJ (coauthor) see Nebel, Anitn, 502 Schwartz, Thomas L (author) Diaphoresis and Pruritus with Ex-tended-Release Venlafaxine (L), 1009

Scott, Elleen (coauthor) see Briggs, Andrea, 1154 Semchuk, William (coauthor) see Tsuyuki, Ross T, 910 Seth, Shiv K (coauthor) see Tamna, Saloni B, 1180 Seto, Winnie (author) Propatenone Disposition During Continuous Venovenous Hemofiltration (CR), 957

Shalviri, Gloria (coauthor) see Gholami, Kheirollah, 236 Sharpe, Michael D (coauthor) see Gill, John, 683 Shelton, Penny S (author) Estrogen for Dementis-Related Aggres sion in Elderly Men (CR), 808; (coauthor) see Boomershi Kellie H, 1195

Shepherd, Greene (a Error (CR), 812 thor) Donepezil Overdone: A Tenfold Dosing

Sheth, Rai D (coauthor) see Gidal, Barry E, 1277 Shoreit, Asmaa Hamed (coauthor) see Desoky, Ehab Said El. 749 Sign, Todd R (author) Inadvertent Epidural Gentamicin Admir tration (L), 1123 Simpson, Scot H (coauthor) see Tsuyuki, Ross T, 910

Singhal, Puneet K (author) The Impact of Pharmaceutical Services in Community and Ambulatory Care Settings: Evidence and Recommendations for Future Research (A), 1336 tek, Charles D (coauthor) see Isaksen, Sune Fac

Skifton, Russell D (coauthor) see Freikag, Vanessa L, 871 Sleigh, Kenna M (coauthor) see Marra, Fawxiah O. 156 Small, Ralph E (coauthor) see Foster, Shonda A, 355 Smith, Christina Cognuta (author) Risk of Latex Allergy from Medication Vial Closures (A), 373 Smith, Jean A (counthur) see Echevarria, Kelly L. 859

Smith, Joseph K (author) INR Elevation Associated with Diarrhea

in a Patient Receiving Warfarin (CR), 301 Smith, Lisa D (coauthor) see Fort, John A, 576 Smith, Megan J (coauthor) see Rabkin, John M. 945 Smith, Patrick F (author) Accuracy of Measured Vanc

Serven Concentrations in Patients with End-Stage Renal Disease

Smith, Scott R (author) Nonprescription and Alternative Medication Use by Individuals with HIV Disease (RR), 294
Smith, Steve J (author) Pill-Induced Esophagitis Caused by Oral

Solimando, Dominic A Jr (coauthor) see Flory, Stefanie M. 584 Song, Karen H (author) Interaction of ACE Inhibitors and Aspirin in Patients with Congestive Heart Failure (A), 375

Sorenson, Suellyn J (coauthor) see Al-Tawfiq, Jaffar A, 413 Soza, Felicia (coauthor) see Avent, Minyon L. 144 Spiegler, Gerard E (coauthor) see Kapian-Machilis, Barbara, 1032 Sprenger, Henry R (coauthor) see Gill, John, 683 Sramek, John J (coauthor) see Krall, Wanda J. 441

tanislav, Steven W (author) Papular Rash and Bilat fusion Associated with Clozapine (L), 1008 Stanley, Dennis D (coauthor) see Brooks, Wesley G. 1116 Starrett, W Grant (coauthor) see Wyderski, Richard J. 787 Steele, Keith (coauthor) see Briggs, Andrea, 1154 Stenzel, Peter (coauthor) see Rabkin, John M, 945 Stephens, Mark A (coauthor) see Chapman, Derek C. 775 Still, Daniel J (coauthor) see Conner, Therese M. 364 Stilling, William J (coauthor) see Young, Melissa D, 920

Stiver, H Grant (coauthor) see Marra, Fawziah O. 156 Storm, Michael (author) book review, 1012 suffer, Bruce C (coauthor) see Uderman, Howard D, 525 Stoukides, Cheryl A (author) Candesartan Cilexetil: An An-

giotensin II Receptor Blocker (A), 1287 Stringer, Kathleen A (author) The Evolving Role of Platelet Glycoprotein IIb/IIIa Inhibitors in the Manage nary Syndromes (A), 712

Stroup, Tammie J (coauthor) see Newton, Herbert B, 816 Sub, Kwang I (coauthor) see O'Brien, Jill M, 1046 Sullivan, Sabra (author) Stevens-Johnson Syndrome Secondary to Erythromycin (VO), 1369

Sung, Jennifer CY (coauthor) see Nichol, Michael B, 531:(co thor) see Venturini, Francesca, 281 Swims, Melanie P (coauthor) see Humma, Larisa M. 305

T-Z

Tafreshi, Mohammad J (author) Medication-Related Visits to the Emergency Department: A Prospective Study (RR), 1252
Tarsachi, Hitomi (author) Pentamidine-Induced Hemolytic A in an AIDS Patient (L.), 503; (coauthor) see Takahashi, Takashi.

1007 Takahashi, Takashi (author) Focal Hepatic Lesions on Maj Resonance Imaging Induced by Trimethoprim/Sulfar in HIV Infection (L.), 1007; (coauthor) see Taguchi, Hitorni, 503

Takeyama, Masaharu (coauthor) see Morikawa, Norifumi, 115; uthor) see Morikawa, Norifumi, 952 Tam, Vincent H (author) Once-Daily Aminoglyo

Treatment of Gram-Positive Endocarditis (A), 600

Tamus, Saloni B (author) Desensitization to Allopurinol in a Patient with Previous Failed Desensitization (CR), 1180

Taylor, Charles T (author) Treatment of Wegener's Gr. sis with Immune Globulin: CNS Involvement in an Adolescent Female (CR), 1055; (coauthor) see Bradford, Gregory S, 641 Taylor, James R (author) Probable Antagonism of Warfarin by Green Tea (CR), 426

Taylor, Jeff G (coauthor) see Tsayuki, Ross T. 916 Taylor, Kelly H (coauthor) see Taylor, Charles T, 1055

Temple, Mary E (author) Interaction Between Ciprofloxacin and Rifampin (A), 868; (author) Rifapentine: Its Role in the Treat-ment of Tuberculosis (A), 1203; (coauthor) see Wandstrat, Todd 1, 833

Tee, Koon K (e or) see Ackman, Margaret L, 674; (thor) see McAlister, Finlay A, 289; (coauthor) see Tsuyuki,

Theesen, Karen A (coauthor) see Flynn, Barbara L, 840 Thompson, Dennis F (author) Drug-Induced Nig Tierney, Michael G (coauthor) see Koulouris, Zoë, 1191 Tobin, Ellis H (coauthor) see Kinn, Jooran S, 116

Tortainda-Ituren, Juan José (author) High-Dose exate-Doxycycline Interaction (CR), 804 Trappler, Brinn (author) Treatment of Obsessive-Comp

order Using Clomipramine in a Very Old Patient (CR), 686 Trenque, Thierry C (country) see Olivier, Puscule B, 382 Triggle, David J (author) Pharma itical Sciences in the Next Mil-

Triller, Durren M (author) Trovafloxacin-A itis in a Homecare Patient (VO), 1122

Trinkle, Randy (author) Comment: Evaluation of the Clinical and Financial Impact of Intravenous Erythromycin Therapy in Hospi-talized Patients (L.), 1371; (author) Comment: Syncopal Episodes ted with Cisapride (L), 251

Trope, Angela E (courthor) see Seta, Winnie, 957 Tseng, Alice Lin-In (author) Authors' Reply: Risk of Drug and Disease-Drug Interactions with Anticonvulsants in HIV-Positive Patients (L), 1373; (author) Iritis Associated with Intravenous Cidofovir (CR), 167; (author) Significant Interactions with New

Antiretrovirals and Psychotropic Drugs (A), 461

Tsuyuki, Russ T (author) Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): A Randomized Trial Design of the

Effect of a Community Pharmacist Intervention Program on Serum Cholesterol Risk (RR), 910; (coauthor) see Ackman, Securit Consisteror risks (tox), 710; (colamin) see Ackanian, Margaret L. 674; (conatrior) see McAlister, Finlay A., 289 Turco, Thomas F (coauthor) see Melko, George P. 1274 Turowski, Robert C (coauthor) see Newton, Herbert B. 816 Tusch, Gretchen M (coauthor) see Collins, Michael, 111

Uderman, Howard D (author) Fosinopril and Hydroc Combination Versus Individual Components: Lack of a Pharm tokinetic Interaction (RR), 525

Umland, Elena M (author) Cardiovascular Effects of Troglitazone (A), 229; (author) The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis, Cardiovascular Disease, and Gv ogic Cancers (A), 1315

Usalan, Celalettin (author) Severe Thrombocytope with Amlodipine Treatment (L), 1126 Valverde, María-Paz (coauthor) see Otero, María-José, 251

VanHarken, Donald (coauthor) see Uderman, Howard D. 525 Vanscoy, Gordon J (coauthor) see Gajewski, Lidia K. 17 Vass, Agnes (coauthor) see Marcus, Esther-Lee, 697 Velo, Giampaolo (coauthor) see Leone, Roberto, 114 Venturini, Francesca (author) Compliance with Sulfor Health Maintenance Organization: A Pharmacy Record-Based Study (RR), 281; (coauthor) see Nichol, Michael B, 531 Vercaigne, Lavera M (coauthor) see Janzen, Laverne, 86 Vittorio, Carmela C (coauthor) see Mylonakis, Eleftherios, 557 Voegele, Thomas (coauthor) see Dietrich, Eva S, 1125 Volles, David F (coauthor) see Williamson, John C, 906 von Brenndorff, Alexis I (coauthor) see Frey, Otto R, 690 Wada, Yuka (coauthor) see Taguchi, Hitomo, 503 Wagner, David J (coauthor) see Garrelts, James C, 1258 Wall, Geoffrey C (author) Calcitonin in Phantom Limb Pain (A).

rat, Todd L (author) Tetravalent Rotavirus Vaccine (A), 833 Ward, Michael W (author) Calcium Treatment for Preme

Warner David I (coauthor) see Haskin, Janet A. 800 Weathermon, Ronnie A (coauthor) see Corey, PJ, 1362 Weaver, Jerry (coauthor) see Uderman, Howard D. 525 Wehster, Guy F (coauthor) see Flory, Stefanie M. 584 Wellendorf, Joyce (coauthor) see Bell, Edward A. 693 Welty, Timothy E (coauthor) see Akinbi, Medinat S, 99 White, C Michael (author) Prevention of Suboptimal β-Ble ent in Patients with Myocardial Infarction (A), 1063 Wiley, David B (coauthor) see Zaim, Sina, 312 Williams, Bradlev R (author) Medication Use in Residential Care

Facilities for the Elderly (RR), 149
Williamson, John C (author) Stability of Cefepime in Peri Dialysis Solution (RR), 906 Wilson, Daniel R (coauthor) see Hammond, Constance M. 1160

Wilson, James P (coauthor) see Okano, Gary J, 548 Wilt, Vickie M (coauthor) see Taylor, James R, 426 Wilts, Geert (coauthor) see Brouwers, Paul JAM, 113 Witthrodt, Eric T (author) The Use of Oral Vas

ent of Autonomic Dysfunction and Orthostatic Hyion (CR), 565 Wolfsdorf, Jack (coauthor) see Glover, Mark L. 416

Wong, Ian CK (author) Factors Influencing the Incidence of Lamoed Skin Rash (RR), 1037

Wong, Shuk-Ling (author) Albuterol for the Treatment of Hyper-Wong, Sis Y (coauthor) see Chang, Sophie, 646

Wooster, Melissa B (author) Reteplase: A New Thrombolytic for the Treatment of Acute Myocardial Infarction (A), 318 Worthen, G Scott (coauthor) see Harbeck, Ronald J. 250 Wu, Tuck Seng (coauthor) see Kueh, Yan Koon, 503

Wyderski, Richard J (author) Fatal Status Epilenticus Associated with Olanzapine Therapy (CR), 787

Yamreudeewong, Weeranuj (author) Evaluation of Amlor Dosing for Conversion of Nifedipine Extended-Release to Amlo-pidine in the Treatment of Hypertension (RR), 7 Yolles, Jennifer C (author) Serum Sickness Indued by Bupropion

(CR), 931; (coauthor) see Alan, Adekola O. 1228 Yoon, Peter S (coauthor) see Williams, Bradley R, 149 Yoshikawa, Kohki (coauthor) see Takahashi, Takashi, 1007 Young, Melissa D (author) Pharmacy Practice Acts: A Decade ess (RR), 920

Ytterberg, Steven R (coauthor) see Johnson, James R, 1043 Zaim, Sina (author) Rhabdomyolysis Associated with Naltrexono

zek, Arthur S (author) book review, 650 Zed, Peter J (author) Medication-Induced Headache: Overview and Systematic Review of Therapeutic Approaches (A), 61

Zeharia, Avraham (coauthor) see Basel-Vanagaite, Lisa, 1371 Zeolla, Mario M (author) Successful Use of Clopidogrel for Cen brovascular Accident in a Patient with Suspected Ticlopidine-Inced Hepatotoxicity (CR), 939

Zhu, Min (coauthor) see Chang, Sophie, 646 Ziska, Duvid S (coauthor) see McNicholl, Ian R. 607 Zislin, Joseph (coauthor) see Marcus, Esther-Lee, 69 Zivkovich, Veliko (coauthor) see Bell, Edward A, 693 ien (author) Rispe

Board of Pharmaceutical Specialties, BPS Certified Specialist,

Cancer Chemotherapy Symposium, 21st annual meeting, 887 Christian Pharmacists International, CPFI Prayer Luncheon,

College of Psychiatric and Neurologic Pharmacists, 3rd annual

Harvey Whitney Books Company, Books and Journ Pharmacy and Pharmacotherapy, 4, 265, 278, 522, 766, 1142, 1248; CA/CTF, 378, 652; Certification Review for Pharmacy Technicians, Fourth Edition, 888, 1390; Pediatric Drug Formulations, 136, 394, 662, 892, 1237, 1384; Pharmacoej ology, Third Edition, ibc-Jan, 137, ibc-March, ifc-May, ibc-J/A, 896, ibc-Oct, 1231, ibc-Dec; Principles of Pharma-coeconomics, Second Edition, 128, 272, 384, ibc-May, ifc-June 879, 1386; The Annals of Pharmacotherapy, bound volumes, 37, 155, 317, 494, 547; PharmaCE, 126, 258, 386, 508, 654, 758, 882, 1018, 1232, 1379; subscription, 3, 140, 273, 277, 387, 399. 509, 521, 647, 667, 745, 765, 875, 898, 1005, 1025, 1119, 1146.

Personnel Placement, Australia, St. Vincent's Hospital, 131 ersonnel Placement, Australia, St. Vincent's Hospital, 131, Charles Start University, 660; Department of Veterans Affairs, 132, 263, 392, 513, 1387; Florida, SHANDS at the University of Florida, 1239; Louisiana, Louisiana State University Medical Center, 661; Ohio, The Ohio State University, College of Pharmacy, 264; Massachusetts, Boston VA Medical Center, 393; Michigan, The University of Michigan, College of Pharmacy, 759; Mississippl, St. Dominic–Jackson Memorial Hospital, 264; New York, Pfizer, Inc., 659, 759, 887; North Carolina, Pitt orial Hospital, 1019; Pennsylvania, Harnot Medical Center, 264: Taiwan, National Taiwan University, School of Pharmacy, 661, 1240; United Arab Emirates, United Arab Emirates University, Faculty of Medicine and Health Sciences, 660; West Virginia, Robert C Byrd Health Sciences Center, West Virginia University, 129, 130, 131, 659, 1239, 1240

Pfizer, Inc. Zoloft, ibc-Feb, obc-Feb, ibc-April, obc-April, ibc-June, obc-June, ibc-Sept, obc-Sept, ibc-Nov, obc-Nov

Wyeth-Averst Laboratories. Sonata Zaleplon, ifc-J/A, ifc-No ifc-Dec, Prevenar, ifc-Oct, 1141, 1251; ESI Lederle, stock ADM machines ifc-lan ifc-Feb ifc-March ifc-April: Vecuronium Bromide, ifc-Sept; Wyeth Lederle, vaccines, 897

INDEX ABBREVIATIONS

CR: Case Report Editorial inside back cover ibe: IR: International Report Letter News and Comm Opinion Research Report VO: Visual Observations

nent, and monthly circulation (1) issues, \$230.00 annually) of *The Annals of Pharmacotherapy*, publication no. 1060-0280. Owner, Harvey Whitney Books Company. Publisher, editor, and managing editor: Harvey AK Whitney Jr. Headquarters of publisher, owner, and publication: 8044 Montgomery Road, PO Box 42696, Cincinnati, OH 45242. Known bond-holders, mortgagees, and other security holders: none. Average no. of copies of each issue from October 98 to October 99 and no. of copies of October 99 issue: A. total no. copies printed (net press run) 5350, 5200; B. paid and/or requested circulation (1) sales through dealers and carriers, street vendors, and counter sales 0, 0; (2) paid or requested mail subscriptions 4935, 4730; C. total paid and/or requested circulation 4935, 4730; D. free distribution by mail 325, 350; E. free distribution outside the mail 0, 0; F. total free distribution 325, 350; G. total distribution 5260, 5080; H. copies not distributed (1) office use, leftovers, spoiled 90, 120; I. total 5350, 5200. No. of issues published annually: 11. Date of filing 1 October 1999. Signed: Harvey AK Whitney Jr. Publisher.

ADVERTISER INDEX

American Society of Health-System Pharmacists, AHFS Drug Information, 1145

Bayer Corporation, Cipro, obc-Jan, obc-March, obc-May, obc-J/A. obe-Oct, obe-Dec

